var title_f35_37_36432="Dx pancreatic cancer algorithm";
var content_f35_37_36432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 638px\">",
"   <div class=\"ttl\">",
"    Pancreatic cancer diagnosis algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 618px; height: 729px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CA 19-9: cancer antigen 19-9; CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; FNA: fine needle aspiration biopsy; MDCT: multidetector row computed tomography; MRCP: magnetic resonance cholangiopancreatography.",
"     <br/>",
"     * Based on symptomatology and the appearance of the mass or stricture.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36432=[""].join("\n");
var outline_f35_37_36432=null;
var title_f35_37_36433="Endosc double pigtail stent";
var content_f35_37_36433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic pseudocyst drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of double pigtail stents protruding from fistulous tract into the pseudocyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36433=[""].join("\n");
var outline_f35_37_36433=null;
var title_f35_37_36434="Exopthalmos trauma";
var content_f35_37_36434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exopthalmos from trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 321px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFBAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ZIyCegz3pMBjjGCKVWbjPQ0pGCwOTg9aAAYHGOv+cUqjd0+9g4FOKEkjocetIq5BxzjtQAAZOdwOe3rS78sDzk96FUA59KlWLIyeMUARqNxULkHODUnTCM27A+UdsGrSCOJT1Y5HSo3UPISwPJzg+1ADIwFyOdwParCJgYK496f5WMnPAFPRDtBI7djQAxAOdnGOoFPx8oJGFzzgdaUDkZxk9TinY3AAfwj1oAaOoYDPfGakVTkZU+p5pY49+AcYPH1qzErbAu4kYPFAFdQrOGIHTGCOKlWMk4A/Xp/jWjpum3Go3kdpZQtPcSkbIkGWJPBr6W+FHwUtNJEOpeJokudQwGSAnKRfUdz70AeX/C34O6t4okW91UNY6QcfMRiSQf7I7D3r6j8K+E9F8L2K22kWUUAAG5sfM/uT3raiRIkCxhQo4AAxipHDcY7c5oAj53e2M00nn5VxUgQDvn27Uu3jHRaAK8hwMlsAdu1Zmp6lBaRM8soAUZ61svDuHIDD0rB1nwjpessp1KOWSJWyY/MKq31xQBl22pyaoW+xMWj7FOc1u2FifKzMm5+9SLPpmlQLBaJDDGnASJfu4rMvfEsUU6KWVVfJ+ZvmoA15YI413Kqg/Sow4HCYP4VgTa4kjoxIWM/Nknt61q2F7aTxqbaRJM9weaALbgyJt24HbFVysiEhx8ue1W4zkZHOCcnPSnvjB3EE470AQwSEKuAOvcVZUnAJHze1VLeRJW2jr1+tWwQgwCTxzQA7OCM0p9QRn6VHsZiCpwPT1qRBkgEA0AVLqDz12OFK9+Kw9S8MWzhnhjAYDOCOv0rqyoIGOvQihkyMHB/kaAOK0G8+x3BtbgHj7vHQV2MEgYAqRzjtiue8SaTuBuYlxIOuKb4ev3cLbyt86/3qAOr3dRgHPak4XHZc8imQndHuDbsnrmpQc55B+tABHkkfMp4pxPBBHHtUeCpy24HqTjFScYznA70ARum4ZIAOM9abENucYLDJ46GplxzljTCvVwOvf0oARSXXdlVHQg9KFHzZC4IGMUz7oDKMEjGDyKkIGOpXB5oAXg5U7sHuKVWyASfzo6kgkbelJ90fMORQAqYwQcexpwP8QHzH1pNoA3ZoG71B+nagBwxgZyBxgHtSljn7wpgyCeRuxinZPvQB+XuOnIIHOfalOexP0pWC7jkk0u/DBjyOlAC4yPRD60MFJyM5HI5qRFJI28A8g+tKqsJckbT6Z6CgBiK24YALH9PerAfPCgDHGD396REAOVAGOnPenKMjhSSck8c0AEaZPAAbr1qWMFjnLDPHNIuGJKkYHWp40GOeR05oARFyAATgVfsNOub6QJaW0sz9hGpY/pWt4K8Kap4s1ZdO0eAySHHmOeEjHqTX2R8Pfh9pvhHQILOKJZrrbummI5d+9AHxn/wimuGQldLvDjgfuTVhPB+v9F0q8BA6mE8191vp9uowIlA68Cm/2fDtx5aflQB8LHwtrUSc6VeIo6ExHitvwr8OvEXiC/jittOnghJ5mmXYi++OpNfZo063JGYkOOgxVqCFIlwigD0AoA4z4cfDrSvBtmDEguNRfBluJB830HoK7cOdozzinMQB79RUW45OOBQA8svPPf8AKk8wEgjGaZtJHHSkaa2hLedKikDJycYoAmyT67cc8VQ1zW9O0TT5L3VLqKGCFdzEtk4+nrXz38Vv2gJdO1ifTPCaxOtuSr3DDcrH0H+NfPGu+JNW1mWSfUdTmncuW2buOecgdAKAPtSb40+CEOE1VZGYZUBTz7Vz2pfFrTZ4luZ7wW9k2fkQ5YD3xXxm0zMqiQuVHIA7UrTuqhSxAx07GgD6K1j442FvLKmm2cs/O1ZHOAOeuK4bxD8RZtcspri4vbq31ZGVYIolHllOckt615UrMuNrBiSORmkyWUhs7QcjB6UAdXP4y1ie2MEmoSuhyOeDx71oeDviDq/hm4aaG5d4gRmJ3JDE+tcMN0khKoW5JIxjr0pcSKoEgI7YPegD3ay/aB1i0tGhisEdmyfMaTufan23x/15b+KaW3iltUTbLDyNzeoOa8MKyRL88DNGegPGaZzli0ZQHqBnp6UAe46h8ctUluJJba3WCLGI4w+SD3JPevRvBnxz025+xx64RGWXBcZOG/w96+SVcuCFZhn9TU3mGBo3jlDdGKjnFAH6E6b4v0K/Z1tr6E7eDlsHP0roYXWRA0Z3I3OQeMetfnjH4lvJbv7TLcO75BCl8Lx0zjrXtnw9+PA0+whsdTtHZFbIZPmAGfc5oA+pfmAOcY9etKBkYPUD0rmvCfjHR/E0LyaddIWjwWjZgGAIro0kVgGQqVYdR/jQAkqLKvI4PHPFchrlk1pdC4g4jz1WuxJCjBUEH05xUN3AlxCUZcBgRQBmaJei5iymCR1HQ/lWujggDcMj0FcU6Po+o7mYiP8Ahx6V1tpMJY1dXDKRkEDg0AWxkkYyQT/F2pzsVUnjA6imIy7VUtg5496kBBwc5+lACKS4DAHB7ZpAw3cH2zTlwAAMY7dqOgKgce1ADCPrkenFGWAdiPYd6UkY545pxAzwT9cUAMXAReBx29KcPvDZ69CaUgsp568elNZcEbsH0NADg3U4I570fKO2Ce9NHBA45PanNwR355oAXI5yKUNwODSdyQMighj0XP1oA/MNzhRsGBgc570+MLu654z0pVTAAHII6jpn1p6ZIOcFuo74oAdGgbhCc5GBTiuwDK7ieeBz196cg2nGe/5U9kJPHQ/doAjC5XgEc96eF+U9cetPxjjHC/pUyITtyfmYcYoAYkbFcbQOPT9a6PwZ4Wv/ABTrdvpukxlpJDgsR8sa92Y+lZRspo3QSwOjNjbuUjNfYvwK8EW/hbwlBdzwkapfKJZSw5VT0X2wKAOo+H/g/T/Bugw2GnwjzgN002PmlfuSa6UZBGeDScYHXNO9D/8AXoAMjjnkd6R2wpUAZ6k5pCSvTFKFBIzkcdaABFwwOMDvTmIHXjvmgnJOPWlK55c/mKAIuWP6Uu1VyzkAYye1Z+raxbachDNukHRQa8s+IXjk2+nXJnuPJjAwqIcbjjpQBufE34p6R4S0mVoZBPespEaoQQDXyV4v+JviLxFcTvJeTWsEwCSRRSYB9Oa5/XNTn1jUHKlpByFTkgc+lX9D8H3F0RNfjyouyD7z/wCFAHMRh55FRELMeeBmtjTvDGoX6jEXlqT95v8ACvS9H8PRQoY4YAoUfe4yRXT2ul7AGQKBwDkHqDyTQB59ofw9BLNLPvfYykFeOaq654Akt8G3KoF4woLZ9817NDYhY90Y3Et83GP51FcQs8gWPgbSN2e1AHhVl4OnnaYTA7YySAgJJrf0vwJ5QBKLJI4IxIDge9esJZMsK/vRhvmIHO2podNkCyDe0mRy44wKAOO0fwXbQqUaOPJwTleBjrg96077wnaXUaRpAu/jlwM/UV0kVtNvRN2dp5AXA78g1oW6PtAaONtrdfbr1oA4ubwXbR26+bFH6KRyT9aydQ8DW8kEiJCHZsbmX0r1BolDAOu7noR+NRtbhoneOJRuGNobFAHz9q/gC4h3fZQXXH3SMZOawJvDWowTGOa0O3Hy7T0PvX0rJYfxYyxAyDx+NRNZQyF1mijXHAyo+b8aAPmeXQ760CyzI4GOCgyBVKRbiJtkmQ5HTpx1r6Wn8OW0vyqpUHJKkVgah4EsLmNla3QFgcOv3lHsaAPFtN1O8sZRNZXU9vNjaTGxU89vpXv/AMGPjBcwXCaNrsqyRllWKQjt3yfavMNe+HFzb/vbCQuBxtbqa5ebS73SmIkjMbLyW/pQB+gVpq1le+WYLhHWTmNlcEOK1QDx83Nfn7oPjDVNHnglimlbyGBVS3Tmvqr4Z/FzT/EtqkN7ttb5QFKE/f46igD0LxFpy3lk4VR5ijI471z3hq9khma0lT5emScEH6V1drdwXn+pkV1HORiuZ8VaY0UwvbdRlSC2KAOnil+YgYznPNWlJPYY6nBrltK1e1uZFZQ0cu3DKxyMiuhhlwqljgHmgC0cYIYYX1FKRkkkgcdqYjEjAOQR0anLwp+XB9PagBGB2gZzjpzzSgA5x1HamN8oPy4AHWljYOARnP5UASDoRkr7DtSFecL0HqetICD0IIoJBkwABjrigBPmXg469AacxBwMEAc5HFJ90lie/ehRno2RjFACqQeOmOtO+fA2nimrnJAwc80AAqCRjjsaAPzOVT1ZWK56ZzT1Vc5OQM8gVIqngYHfNOwQ3pnjrQAwKCTuOQOwFTRrz8o3DrxTVGGIIIwOSanUYDAdfXnpQA1VOeEOc4ANex/s9+Ak8Sa8+qX0W6xsMYVuVaT0/CvKIU2gZA4P1r7U+Cehf2D8O9OjIHnzr9olPcluf5YoA0dW8E6NqpRbyyidEYOuV5BFdSFCRqq8Y4AHpSjqCKezZB4HPegBFJ2DnPFIFBIPbrRgqRwefyp44HWgACg/T0NGW7AHsaR2x25NZ2oX4gXy4pE+0HBIzkqM9cUAXLm5htIy87hF68muZ1XxDLKDHagxqf4v4iKuT6X9pBMsrMTyS3f6VlXekQ28bkzNvPTJ6UAeeePfFEOhWEk9w48wcKrZJY187TXes+M9Qdri4Y2m/czEfKg9q9V+MH2HV9Vt7FJjLbwE/aXXoWH8K+p9fSsbS7CJthSIQwR/KkSHhfc0AZ2kaHa2C+XZW6nBy80n32+npXRWun7lTeSryclm4xVwi2h8pMO83Viq/KMds1ZsYzIXJQFcnKk4+lABbQqjBWlT0zjitS2hCgHOSQCW5GPTj3qQLCohlMbs/XbxyfTPYZxzTVjub1TNImFdj+7znAHGKALN1KBCqkiVtwBHbPv/APXqnjzJiz/Nn5cNjj6EVetrFVidiWLZ6HoP/wBVTx2arsZM7SwOOxoAW2ijQLtQlRyWIOM+gNEsJMITYMk5IzV9I0QfeZmJ5B6e30p/lNuIePgDcCD1P0oAyrQMIBljuyckr+gq6v8AEHCkdmApJVYA4GAO5/hNEbtk7vlH9496AG+WS7c5UngGkUSsy7Rnaefb6etTKBNHx97oCPpSEBWCnPJGNxJzQAshDoDGSHBwVbgioHhBwJAQD1K4qQ7Y8mQdRnufapUzzu5UDbyetAFTyjDK3Xn1qNGyXwjqvfI6VoMpI7n0J/xqGVDJnaDg9vT60AV0hBZXDLx6enr9ay9U0K1vYmSaFcsTg9evrW0sbIQuOMcYGCalbLEheO2AKAPEfEvw+aFt8UjDcTgqM8Z4FcO0F9pN8JDJLbvENyyJmvp2SJZFMco8wEYBP8q4rxT4VguF+RdyHPUZI9hQBynw7+Let+HNXQ3NyLrT5mVJVn52Lnkgjoa+v9O1Gw17SY7qwniuLeZAQynPBHevhPxX4WutJuXECGaAH72MYrS+GnxF1TwRqcc1lNJNYnKzWkpJX8PQ0AfUs6HR9XZ54y0WMIAeBXX6Jfx31ojJlTjgGvP9B8eaH430nzvMS2uQTlHYZzWl4b1k6fMtpJtkhLZDemeuDQB6CpwSGG4H0qbI/izgdj3qsrqQrDOOox6VYRmIG4nJ+7/hQAoBIB8zHofWgEoeTjjn/wCtTxk8lMdKZMBwT19hQAqkHAZSD06dRSnH8PTtx0qJM+bv3Zwe4qYdDs/OgARsr8pB7njrQdxHQnjBA7UpxtwRyMEntTW4IHIJ5z1zQA4+uduAMY/WlA3DKyHH4Ug56HkevFOUccBcUAfnHd6be2TFbq1lhK8HcpHNV0RmC7cdMkk19zap4T07VbaSOe3Rw2c5XNeD/Ev4SDTreS90RG+QlngPOR7CgDxNELDkAAdS1TxpgAcA4496dLFJHIyPE6Ov3h0NOiTOTjgH8cUAavhrT/7R17TrFSSbi4SMjsMkV942UK2tnDBGAqxoqgDoBivkP4D2B1D4k6aTGdturSn0GBjP619hY+Y4H4UAOUZFKFyAMEcUqA+vA5qTGNpznFAEe4Aj26ZpS3GQRxTVBZssOajlY54/KgCLVLk2lnLMTkgcZrzWLQdYk8++mvZpZb1+Vxwi54A+grvtailutOliXA3d/Ssm11N4I4bS5Kp/DuJyfwoA0JLmWCBYgu5lUKT+FeO/EDxvNHeNZWMo3g7ZCOefY9q7D4t+Lk8PWbWNnJm9uIzlgR8gNeCWu6dxcSEsSTljyTQBL5D73kLqszHJZj61taRayzuqE4ZjjPTIFUobaW4kRVKAAZICck10ljBJgbxyARtII/H/APVQAlrYlS3zfITjceQcH86tWtuElTYm0+3Iyav2dhMyrJNlWJyFx2q7bWywSIyOdoBwpHU560ANgtQigzN+9PoOtTiHagCABR0GOlaVvBmYkgSZ6j+7VxYPkO/AAHQCgDIitWkAO773XjpVpLVEjzLIMqeAF5rQ2BUIAAyOO/NNuIlyBtAwM8880AUsx9ScDGeO9ReekhH2aVTwCUHUe9SyQs52Jgbgc1HBZC0UtDEMnG7nr/jQBVumLSY+YnHeiJgYgec9TuGM1e2rIpfaAenHf8KYIPkfvju3SgCk8gjzt8tVUZOO1NUnBLEYYjBxnH0qV7USlkkixnnOOD+FO8lSM9FxjjsaAIXdScsB3BHrUcbztMojZHt+pB6j0x7VKYcIcA4yCM8/U0qKsYZVAwOMjv8AX1oAeqgv0YAc/NTVcM5BGTjnHQ0suzeGyQMZIpyEbMspZR3A5oAbIpZiWBOB0FRgE7R3B45xVpvLfCoTnoefT0qs8RO4ozLIThSOfpQAkgJAG3GDxg1XuCkkJQ4XjBOMZzViLcPlYlZOhHqap3JfG6MLv6fN0A/xoA5HXbOKWMRONwydoHYV4x4psVtdTkCgIxPK4r0nxtJeW8lxLHOIy43J1DD1IrzPxBeSzTzPcMMqmMKd2fegDKgna3ZmWV42znK5Ar0r4fePr23lW31O5823Vf3bH72e2TXm1uwKySSNHtRNwVh19gPWoEkHmAwqw4yw6HOTQB9/eCtY/tbRUmLI+Bjcp6j1rpUK8BslcflXxf8ACj4o3vhjU7VLn97p5IRx6Cvr/StSt9QtYriCRXim5UKc4BoA1EIyCCc8nr1pXbD5VgAQfz9KjjOBlTkdjUmQTggblHPHagBj/wCr2nr3/wAKfGVCIvIUn9femvxjLEqx/GlQnpuwfpwaAJI8qOSSe4JoQMpJ4yTmkU5QEg8eg60YBPC/pQAp3ALkcEc89KkC/wB0Ej13VGpyvHyk9B1p24rxsU/jQBkSJsYkdDWbqEKTqyOFJI6VscOgOMfWs3UEZVDpQB8+fF7wFgyanp8YjccsB/FXjKx7XO5OVODX2jqtvHfWTo6huD1r5U8d6N/Y/iCaNQfKc5UEUAemfsv6cH1vVb9gcxRLGpPbJyf5da+kh8xPODXjv7NelSWfhW6uZ0KPcz7gSMZAAFeyDA69aAHpuyRuyKU52nPUmmAHjt61j6n4i06yuGgkmzKOo7D60AarSbUbaMv2xWK94bMvLqEiqSc4B6e1Yd14qj3D7JJlW5JIrifE+s77tYjOZbiQ/cJ6A9hQB2+u+LUeApaQl3/hVeSx/wAK4G9uL7TZ/wC29euEV0J8q2U5VM9AfU1zfizxdZeB9NZdPYXOtXAzuc5EZPYfSvMb7xncagI4b25nvrmRvNlk5Cj2X2A9KANrXNXvte1WW4mHmSOxYuc8DPArY0qxYQ+bNIFRj82Dub8q5/Rb2Gf7pb5hkBVPPtXoejae0+wRhggORgZUex980AWbLToY4oyiMTj72M81s2sQfIjG5hwuc5HvVyxsGWIB33M3OcYA+mK1rHTiECqoGR6UAY9lZXBd5ruUyMPkAx0H+eK1YrEqgAXjGct2rXSzAbbnJA44x+NL5bxqAPlDDH4UAU4IGUbQvHUVYjiOdxyFHXipERmf5SAR7dqsKCqEL+nQ0AV5IchmyT6e1V23NhQenfrV/au0EnJ7ZpiwfODnB9B0oAzimXA54Gc+9SMhwdvX88VbELq5yu4deDUkkAIPZwM/jQBQMKsQdo+mKjaKPeeP/wBdWn3rxuUgjr7VHhUCsTlgDuoAgMAZFOAvHUCoJLZSjBRjrnHaoJ9b09WcC5jZkOGCnO3HXNZ6+ItPuJJIoZQ0wGQMgce1AF827fKRyRxknAP1Haq8sGUDRgdcj/ark9T8Zpb3DRwqswA+Z2cBRyOn51EvjyzAyIG3Dkgc47fiM+lAHWqGbaroB6Y61IpZQfLBVhxgDI+tc/Z+M9MmWNH3xTMPmU4O0evvXQRSx3KrLb4dD/Epz0oAFVSwPH4ccetDRnoQSpGcDoD9alaPLFYyM/e55/CljikjU4+9jn3oApHGZA3JIHzEdKytSjKAPIT5RBGVPOfU10D7ud4XLcHB4/8A11Ru4zIgGRvOOMenOP0oA8p8U2IazZboymQAktnO30P0ryaezufMkIgIRScsBkHJ7/ka+hdfghk8x5mdBGBlfu7h6fQ14540i8u+lbyYYoeJFWIlQwPQ+9AHGyuGcxgEueMnoB3pCArgKxj4JJ7VZMTKm9yowu7Dt97noKqTbiqs4DqO3UYoAVJssflBz/d4Oa9u/Z++JTabrkGi6lPIbKUBYXkG7a3THsDXhhLOWmUhWGNqhe/pRDPNbzrNHJ5c6uGU9MEHrQB+kiFTGp49fSpwcOCDj9a8p+CPxKt/GmgQ297KqataoI5gf4vRuPWvVVBOTwQTjHSgCRQCHC9v4jTTuCq2P/r0R4ST5voeafgKSCwyOntQAsfT5SwBPQ0/ByCh2jHIx1qMEjOfYAU9WG7OG59uaAHD7xJAOe3pQAGGRjHuaauTtbJKjjrUm0H7wBNAGCrlWOcEetSXP7yE8DBHaoN6uDhuvI5qzbQsygsSFNAGEkUsspht1LN3OMAU228D6UdQOoajbR3d3jAZxkL9K6dYvLGI1C55rhPHOrX1jqflpMVg2ZIBxQB2Et3Y6dF5cWxcdI0rIvvEcqKzRqsaD+Jq8qv/AB9FZI/yq59c1qaJqses2azyAtnkj0oA19Z8b3MQEUcxdpQeUHSuOS8n1rUo05EaMDIcncR7/WsnUvE0T+IjLb26SW9svlIo5Jauj0xpthuJ1jS5k/hHYdloAdrWoNp0rTQwr8i9SOB6CvPfil4lbwtqdskEiXGqtGsvLZChh94+n0rb+KeqnTtMFpEirdT5EfcE+/8APNeNTQteSpc3Blu5htD+Z/ER2PHTgUAZOqXs9/e/bNRle6uJRnGOAewGP51Ysb2SCaJfsjyKDllEbcA/zrSi0UtOXRFV3bdkYPB9PT8KupZ3VjcqRdzhwCpD4ZcEYOc+1AFG2M7XDT6IVCK2xYmGJR78jAz2X2rufBfjRkuR/aVzOvlKPMQjK5/p+I/GsXR9Rk0e7l8yzgntbgHOE3+UT/EM8kjtzxWkYbWaZLxJI5wcgGKPABAxlmHqP1BoA9w8Pa7aaxJCLKXzFddxHdR0rsoYlUCPeNwGeeleMeGtIaxZfssQt4pGzFMZDiQADgkfdB/nXp+hahFc2gCNJMquV3H7ynOCPegDZEYwCAWI7k5xRcDYU38E1ZgChyFVjxgL70ybabgZIBXrQBCkBHUEMasLbgx4VeO9SQshfIIweAPapwwBz93j17UAUHt1BKvnBPX2p/lMV+UcnipWk3OT0JxjmrQUBeDwe5oAobFzgAtjiop8IMn5R0JPH4VsSwZjYg8L09jWFebIF86c4wRhDz+IFAGTqFyU8zy1+6NxVjtrzvxh4nFnMsP2iJLg/M32ZN7IuP4if510Hj94I4ZZru6tYYEUAec5AZj3GOSfQAV45a6PLrGqlrcXa28kuyFW44xyzHt9OtAF+516S+l8mwsN9soZpFKDqPvFmP8AESasx2MxhSS5VpYWGY4IeWbnGF4zyTjOK3tI8IyR30cKxGKztItibT8zuSCX57k/oK9H0jR7G03SfdlYBmk+8U2jAUfrQB5xaeEr2+m8ySPKbhH5CfdhHUjPfHf3re07wXYwLF9rt42kzuxGcIozwD6+/rXoEWtaFaKsUDxRHH3WPc9TgdTnJpza7ociFZph05byjz7CgDgNR8IafOSyxfN03xKRkDtms608O6hoztLp7mJOW8hyTG36/KfevQ7nVrJpSls6lVOQ2MZHtUMyRyju3GSKAOb0nXIXxBdo1nck7R5g25/Hoa332MwdHBGecDrVTUNHt9QRkMcIiPOwjn6j0PvXPm01Lw6paOYXFoDzGTlgPUGgDpAFJ2ZBJPU8VUlhwjMu4tuIJJ6fSjSdRivVeW3KkP0XdnH+HuKs3WHVRjvgk/lQByniOINayERbmMeemeR09uK8s8ReGbi9015pbmNplHGwYB7gfhXtc0TMhwBgrge4rmtR01WGVRXAGPp9BQB83WwWK6f7QCVKlXjOMFgeAKZO5kZtqrsJBRVGNq+1el+MfC6C1cWsALIw24PCL3x/OvPtaiSK4YxOzKMAlOMkDsPSgDFRm835Dwx6E/rUiMiklm3KBx9ajjRNyYXDE9W6H0qOTOSfunOCB0/CgDe8IeJb/wAL6/DqmmTtBNGQGA6MmeVI6Gvu74f+KrTxZ4Zs9TtJVPmA71xgqw6g1+esed6EHeQPpXqHwP8AiNP4M1pba7kcaRcNiVQeIyeNwH86APt8sxkUYJUnk1MSdzE8Lt4rM02/ttQtEurSaOWCQAqRxkHvV9CQAp5B6HrQBMnzJjIOeaT0BfPt2pASGJyMZxS85xt+YfhQA4P1GAVz1FBbB4x+lEh4AJORjjtUmwNzwfwoA5ewsJBendIxhAzye/pW6QO2cVBYA+QSwJbPTNPup47SBpp2CxrnOaAINWvlsLXzPvSE4UV4J8TdWnmWQmRjIxz8vcegrsvFXinzrh3GRbKCEArzLX9USWQyiIuQcDjJ/KgDihbTSxsz7+nWvQ9PvJbTwA6xxbJ2Hlo3TcTTPCNlL4hvEjggwmfmyvFdd478PDR9E0yBCoZ5sn6CgDivCuhQwXNnDc4eeWTJbqBjk5rp/HWtR+FdAbUoGiN68gWOJudxBycenGeaqeCJhqfi62t42Kx28ckjhu2FIJ/WvNfHss3iW7/tBHEdjJK9raQ558tcZkAxnDHqfwoA5zU9W1DxFq8l3ePJNLO/7uJeAi9gB6CrNvZPPL5ThowpOQOB/wDrrX8L2ElpJPd3McgEYUM2zIQHjg9uM1NJBHcTyNHwpLHAHGOxJoAs2NnbRIpUIyADDseh9KoayyTTFUZP+ApzV6XRruaxjubBJZo2OWMRDFB2JA6dD1rnbq3lQNJ5m7nDbnwTQBXuC8LAZdCnIYng0ljut71L3T2MJRt00a/ccdyR6Vb0ZLVxt1AE2jNsL5J8knoSPTNSzWSaR4mit7iQNCrr5jgdYz7fTNAHrHgjxVa67vtGjEMyqCLcNllUY+b6HPSvQ7aNbcqUjBHcAYOD3r51s7LbfDymktn3f6NPGMsOSV+oPvXq3grxe1wrWus4ivIG2vJj5W7BvYHH50AeoIQGzuO4ev06VDduIwW4GOPr7VWjvkkiD5+Tru/+vWNrOtpvRImDEsFAB5HvQB0FgxRSzDgnP/1q0ELSOGHAJ4PauetrpQi7m4xWik8TKSG5xkc0AaChGXEmQAOCPWkScqGVwGjBwrdPpzVJbgbV53E9c0x5wyM/zEMMlVPWgDbSVmmVgcqAfk7+x96yr/y5W+UZYHG8nlj396SG5OwAEhD0+lVrjaDvB6kjp1FAHPalo8d9eedL80i52Myg+WMYwPTvTl0+0t4o5AEgWNMAdhkcnn3NWdSvI9Ot5J3IUr1BI59OP0rgdV1C61aRo3kKW2QxQnlh6k/0oA2r3xLCkot9NjM0oGBIThM/1NV7SHUbuVp7m7kELJyitsGc+lVdHsAi+Y+1gq527cbBXR20sflKwIIx1IoAjtNLtIseYFlZ+fr7ZrRstMtraPZDbLtBJ6ZAqCSZIkZlAKjuB1qxa3pMZ+9gfex29qAI73S45oyqiNSOd23+dQC2mhxiTZxgAdFrR84kkZGQM89aRyDgtwV60ANtbkP8kv3z/F2zWg6hosfKR3LLnBrNmhUjcSQ3qRRDctEfLc/KeM560Acvr2nXNhe/arEJGw+aTav3x128VtWzCeITRqxVlDfMc8fSr11bmZZNoBz1Gf5VSht3iRTH86dGX/2agBjr+7wNoJHpWVqEal98qgJt24HB+tbDockc4Gc//qqhMFLhJDkgcA9aAOb1eyJtpURyGjAYL2Ix3ryLxpZwW6ykSAyMw+VU+VQfT/GvXNYH7xgdytjJAfk8VxOv2sN1HOl1s2xDOF478GgDxUqskihJgABgbuMYqI8bmIG7GCScEe496ta1AIr2RAQVySpAwPyqlnKAbgCAdo980ANbBboT9e9PVlEndskdaag55OeMA0rZPJ2gZoA9p+CXxTuPDEsematNJNpMmVUMd3kk9wfT2r6+0i+g1HTorm1eKWCRAyyRsGxmvzhtD0GS3fjjNe9fAH4kv4bu20zV3eXT58JFuOBC27nJ9P5UAfWZIypGMgdfWlH3cnBOM9eahgkWVAUHbd1B4NSseNyrwT69qAJRkAZA9gOcU7B9GqMcjnK+3rQU3cgtjpQBCg+Q7cA9qwPHEUkmis6DIRwze/1rfZ1iiLsOF5Oelcx4m1m2ubCWxtSzyTDbnsBQB5D4jnSVXCFdx6jHNc4LV2cFFLgkblx+NdZqvhl0uFKl2i3ZIz1rlJbrUJ7+aCzQQpD97IwfSgD3H4Y6Tb2elK8aAO5y3HOa5z45XBW80q0UnJRpCM+4Fbnwn1mO8042TPmeMdCea5/x7CNc8aGK1eOS4hxb7WbAAAyf50AedWVtMljqv2OTbeXqC2V142q5ALZ6jgGucup4LzxFKf3jW1mBZ2qA8LGnGc+5BOfevR5rKHSLbUrmUbEtoHyGGSrlSox+ea830HTDJbxsElkZm+YkYU555NAHqFxo95J4ejsY5rdkliKsIwMIOqn3IxySa801m90jRDJajUbe4uVOwlew9eO9anjO+ufD3w4u3tZ5hJfMlsOcbRkk474rzH4eaFp+teJ7TT9cupIY7hWbcp+82CQMn1oA6GDXLvTZRcWlzPAWIIdG4YZ74/DiuksdPXx/dW6WLwWOpdLiKQfJLz/rQR9eRioF+FOsaTpsGoXFza2+k3MwhPnS8AZI3MO3TPrVG8sdU8Dauk9sRuiJMFzGcqwP16rQBl+JdJ1Dwlr13pt6ClxExSRVbKOpGQfdSKpaje3N5b2jurSPEvk7sZJA5Gf5fhWrq8F/qGhnX75mkSeUx+dI3Lv12genoelZ2lanaRQJFeBh8+AQvagDRi8688Mm4iUlbWXZvB+YdwPw5rcsdft72ztdR8ofa4XMNzFu4mjx8wI9xzn1FYuk3Zuzf6VZsw0+S3dlBUbmKjO7p65rkrC4ktNUWNM8ttcAZB9KAPSbnxlcWDS2tndNNZo2Ii2BuXPBp+jeIbq5u1nzIAM5EeWyfYe9cXb6NeX96iMrQxKeWYdBXt3hfRrbSbJEhjGTyzA88+lAF/Tru4njjJikj3jcA/XHvW7ZSXKqCcAd+KhgaIvwuFzkGtWN4lC9AegGaAFWcleRjH50sVykTjJ+U9SPSqN7ICGKZyDjA9PWs+G7KuRLkADg+poA61iqrujIBUgkHjNR3M6CFmG0gcn2rmL3VxCmZGOwHknmmX+vwPpqyRS5LYXKjOSenHagDI8Q3MtzKVm/eKvBbPQVl6e8cbBWZDHzgHv6Z9RWPqupO9w6D5CR9efeorW6RMEvn1+vtQB2EUpV8GULH1IAyAfTNXotzxg4JDA4A9u9cvY3Syl4pZgpUhhuPGOuPpXTWE8DQ5g4UAfdoAu6fC02UkbKhsYz+VbkenKIF2qNxyAQKx4HxcJ5nG5c56ZrrtJSS4B/dkgDhu34UAY08aRIMg+Z0X/GoImVmPPy46Vd1wLESGcxkDJAHU1jNcnsUwDkA4FAFtCx4ZiWPGCKguVZkGcq3p6Ux7oKzMrjHoKgluMhgrcj0OaALVtcGMAFue5I4rQh2yIJFB2HIIrmUucvsYkgjGSc810GkvvhUbW3ZxjtQBKIUmBZN4AO0g8HP+FULi3EsZZB3OM1vybeSGABO3B45qheQFJN2wlVzznGRQBwPiG3dCyMpfPQ/wB0egritSiWZcvhduVDZ/T3Neq6lDvUhhuzna3UivOPEti0Syu2BtPDpyD6HHtQB4v4x2nVmliKhsfe55IrBBYbmYAg/ePTvXT+LYtt5MyuCf7zDrgcmuUicqQSOGIBxQA+RB52EV1QjIB5PT8qjOMnPGPWmkkArlsg/lTomx3GPQmgDrfhnoVv4g8TQWd3KUiKksQeenYV2/jHwVP4WnSRAWt2f5T29RXA/D7Wf7C8T2V26DyxIAxbnCng4r7J1Dw7Z+LvCsbgB4ZV3Ifbr1oAyvgT4xGraUuk3jbr2Bf3MjNkyL/dPuMV6sjK6q69COVHrXypHYXfhHxArwAq0LZjY/dP/wBavo3wjrsOtaBa3qhUuCMTRjjDDjigDox1wN3X1p/HfcD/ALJqFSuCTk88EU87O0mB6Fc0AV7khWCSEGJzgnPWuf1XTIYWV1QCJj6dDXVXEImgKOBjsQOaxDFOd9jd5eNh8soGPzoA4jxK00Gnzz243yqmVUjOTXCXl7FbXC3UQC3koUyKRhSO/wCNej63BeWttdRiEPcKhMan+KsBLCxutNtbi4ZY7t+XRx0GewoAh0e5ttBvbK8lZreW6OY1BByM961zptzJrUs6xbWmkL+Yc8575rjLS20+51S/tL8SeZbnMLhsBl9q9Z+H2rx6lpbQg5MDFV3fe29qAPPPj5Zy6b4K097XzZPNuxHeMR8pUo3X8QMe9cJ4du4HsJCmPM2BdnIzjuDXvfxVW3uvBmqaa4Ek91ay+SmOSyqWB/MV8jeHdZ2wor7vkAGM89f/ANdAHeeLtIvde8D3FtCTJcWbLdIi8lwAcgfh2rxaG7e1uYLuHcLqBgwB7MvT+Ve/eC/E9tZX6FzG8DYVgfRuMn6YrU8Z+B/Cl7qkckliiz3KiRjbvgfhjj8evNAHl1h4i1rxz4jjs7y6+z2ty6meOPLIgHUqPU4rsfEhbXNbg061KlExBGrHI2gdc1qaj4Q0zwpA13oYDWkrhM4yyZGcM3Xn1rjZPEZsNRjv4IR9tgkypHKj1OKAOm8bRadYaZa6NEP3NjiWSNjjMhGP/r/jXlM9ol3dM9vA7RjoCBxWx5d94k1W6vbtZfILktOehc+vPFXri+07Sd9raiGa5dgkcmSDkjH880AVfB98mmXmoXKSyQXMUJgjbClSrcPkEdhjpzzSeEfDF3c3k+q3qGC25MCsMFufvH+ldp4A8E3FmzalrSeVP+8TyGZZI3U8Bj+v866+3gW8mieJAtpHgRgDhzjqf6UAYuheHnnkjmdCIwAFTH3vc/Wu3trBtuZR0P0p6QSW8YeSRAQPugYArYgVGhV25BFAFRNPQR8Z+XketZtykkBLHoPfrXRjOD5Y4HrVO9hd48hOe+elAHMS3THGwjzAPu5/nVYStKnmDrk/Kadq0BXc8YAkQZOKzLS5XlXby1IyRu+7QA7WklaJ4wcptBOP1FcjHJNAzCbc0cfRXJAPPUgV2ruZJljJOwtwe3SnDR4HkaQKMnuTmgDznxCLiG3eUwsqDGWT5hzjnjmubtdZuZC9vFpd1cP13qpUDHfPSvTdc0C5hh8+zYlOMpuyeDVSOVrsTC6kw/CYPyhu3X1+tAHE6VqGqX90Ibi1Fuj/ACtI3BH0NerWPgnxGujQiw1mErgBkCbmIPHXPYc1DBoNpPdLIjMGQBY+BtHB5z3Na2haLd25Vbe9myMCRi+C59j0FAEF14R8bWDyXEN9aXaRIqANGQXHcgewq0NT8b6VarJaabHeFVC/u325A45U966G3v8AWFum8uWdYedqH5iewzn86uz6vqESbD878ZBjGQcflQB5XP4x8T3Xmx3OgzrMkhDnyun+fWqR+I2lIzrd28tvPG2GjkBG33rvdc1S5ScSKA7hxuAjIA7bh7D3rzTWtHn1DxRLcy2gkjmRlkSOPhgR94A/iaANWXxjp9xbNJZ3kZXIOGHIHcY/rVdfFkN0vkwyb3XO5ox+tee3Pw51GVUaF5Y8k8ycADsD+Fbml/D/AFnSZA9xN50ZGAU4A475oA7rT7w3ECD5lOANuM/jXdaEZBaEYwAeuc15p4Yt5GvRHKzB0PAOe2a9U0uMpbgFQSOTQBPptteJbut3defJ5hdHKAbRngY74FWp0ITBcH1zzmnwyKsgGNpyetLeYZQV7c49aAMC/hk89X2r5YBz9K5XxHaia3k+Vt2ABgDB967TUV3x4HIY4OOwrnr2Ty7d2XDCNDhcZOKAPAPF1lJE7nYVLJgED1zmvN5o/Jn2llyp554+le7eMrVLvT3uIDludvy/dAPIrxLVIWS4cNgc7fTmgCk55OAAGORg8YpBgdBhjzT4SqsqvHvUZ474+tLKwAj2BcKMdPve9AD4v7wbDAcDHBr7v+CV0l78OtLcKVVYwpDD7x7n6Zr4NB6dCAO1fbH7PIdvAlkw3rGUATeevqaANf4leGV1GyM9rD+/Q5BHavO/C97faJfxojyLGrB5ID91+3+TX0G0YkjKsODwa8y8X+HWtLprq1jyjHrQB3un6jZ6hDb3drKGRhjbnlD6GtFGGOcGvK/CWsJpUqR3kYkgduvQoP8APNem28iyxB4SXQ9CtAGkPvfrmmSRBhyR7VIB7jg9vWgnnDCgDN1C0F5EFYAOv3Wx0rznxLaraagry22VYbMgfdOf5GvVJQc5XOD2rmvGdgJrNbkAkKw3A9x60AefLo0DozyJGAH52/eINaXg2GOwvBJaoyLMxVl9PSp1tFmeNomG9TjrjP1qyxS1cnOZQcqFP86AKnxKYQwC8+Y3cAXYvYjcMg/UZr5t8UeEm0dm1bw+7TaSMPLD/wAtbVj2ZfTpzX0B4jkurqxtZLzDyySMw2jgJn5R+VczfeG7PWLRklL28xHySwnYy/4j2NAHi1hqjLKMgxBvm5Xggn0rqLLxZNaSWhWQTWsEwkEIfG49x9MCtDXPBupx2pS702PU4IhkXFmwilUf7p7/AErzuXw14iZne20u/WFSdn7k5I7ZPrQB7dbfE3RZrOa01Gxkt4JGJKxfMGU5GT05HtXl/i3UdIj1Z7rRUaGzAASOd9zZPr3xWfYeAPF98+37BJbI3WS4cR8fjzXS6F8LoBcqdUvzeSrKuYoTtR1HUFjz69KAOds7nUdUhubTR4prxXIZnwVCnHX0Gea9E+Fvw3+wXCazr7iacjMMWPlX3Oe/+Fdto2g6bp0ZxClvaxLkxL9wY749amvLpp1lkuJfs9ki5VScEj1P+FADdb1JLq8XSrH51JxO6dAuOlaS6XFJpJtyTGpXAI4K+mPpXJeH4xPILmCQKN5wFHOAe/tXVXF59hjnmnlYwJHv9OKAHrm90YW7Sg3MfySOD97HfPrXR6Jpk9zbI5H3BjnvXn3hjVYNQulV7hV82RpB02hB0Ar1vSruJbBUtgFz3oAzQjZYFdmD09xUUilyy847itKeVXYtwfrVUAbTtxg+tAHMa3pzAiRc568dK4XVrbYSxcCYsMKw++M9K9eliJXkAqO2KwdW0e2voyskfOd2aAOHsLj7TGUIYyxjoe4ro9PYugRj83GR3auT1XTrnRrszJKZIQT82PmA9CfSt+0nDxxyxtgOgPXBWgDoPs0ZABGWHzDjFZOs6HFKheEKkjDBwOD9a0LB2Xe2cs33vm4AHep1ljlwPl68jGKAOasbZ45D9ncR85aNuVJx1A7fhWpZyvZIftMEqKeCyfOn+NT3NtDINzDa4PBDdKLa9lt5lM4M8I692HuR3oA2tMvbORBiZGIXb1wR/hWj+6eMKXBUjJBINU7KPS9QU+X5L56h15J96u/2FbRoWWB0LDny2PP4UAZd3ZREO3OwnAHp7Vl/2dCJg2dwx0I6V0MmmeWMLLKMZ4PNV3tWibmTPrkc0AY7WMZDBUBB7EZqveWp8v5jkAcA+nvW3NDkBSSOeCKydTBTeDnJ9eeKAOes7eMaojo2MDBU8cnuDXZ2yhVVgecYxnrXILDdssrWnlCfkx7umT2NdNprznT4zcoPP2DeF6Bvb2oA0xJ5jAYGfX+lJKAO+PbtUUX3sjr6U6Qhi4BIYcfSgCrdptXBHBweO9c9fDYz7kGAwOBx3/lW9ctuYqrYK/rWdfIGhY7BuyOAM8f4UAee6rYFUnWMYRpDx1HPSvFfHmmG3unlX5fmyx7fhX0Bq0UaM3n5kQvyiNzXlHj+1gu4JWiDKy5A+YEj60AefeHbbSmS+k1u6mi8mAyQJHHvDyHhQxzwKynChFJ/1h6gDFIQEOAQWB5A6AelNBJyQQQo/KgByqWbbnGevpX2T+zCbs+BIlcnyUlcFmbOef4R2FfGm7gkYI6V9I/sw+N5FvofDdzCEiMbSLIpySw7EUAfUQ79xUc8KTwvG6gq3BzUi4K8ZxTsjbjtjFAHlfijR/7PucgHymYsD2FX9M8RwCzjV4pd6jDNGcBiB1x9MV2Gt6cupWrRdOOuOlcDPoktnM8J3HByKAPWk4TgjB6cUmPbv60pG4rlfpzScDOepOcgUAI49Qc+1U76HzbZ4XPDcDNXsdcNyfXtUc0YkUqAOn40AcdPYC3kBA5B5BrIv4UmstUDLkqdw9RxXdyQbhiQBlzjkVy+tJDb2uuSrlmVQAi/TpQBzOpRm40LTp+phXk5zVSwVGdcqQew61b0SfzdHhgnUpJNCCqn+EjtVXzkjldkYjy+GUdB3/GgC5c3FwGEUNnI+eTISFUe3vQDNDbZuZ4bZcfNjnArn9Q8UeWDDaHz3HU4wF+pqCGC6vJjLeTmXIwAc4yew/xoAtSatFfhjYtI0anBmfgtjqADV7Sog43RD5ByGxjd9TUekWLBx5pRpDztPT04rqLSCNAokUgdRxwKAOU8YSOP7O06LI+0u0s5Az+7QdPxJFU9Q0O51m4B/eix2j92RjJz3/Cqnxg1c+H9e8NaoAGt0keGcquQFbFdZc6ukOl+fGC6lNwx0IxQByN3o95pF/FJYDdAcl1c9Oeg/lXlXi34iXWo381qrPEsBZShHfONp9qh8eeLfF9xNPcxXDW1gr/KsKjIHOMmvM45Ga/WS9kYiSTMr5+Y56mgD034Qx3mqeNbVY5HaCPdJICPlA//AF19WWcqRjrgAYxXnPgPSNH0PSkOiR7YplD+Y3LPxwa7CC4C/KzqTjPXBNAGz9pUngg47VMjAAdiecV5J8RPiMfCxjgsrA3t2/zYLbVQe/qfavJNV+OXi27fFsLSxAOTsjLH9aAPsBAkqj5u+MZqC+gCZUYI7gdq+W/CPx21exvIk8QRJd2xI3SRrtdfcDpX0pY6xFfWMM8JLRyKHU+xHFAGfqdvHPA8TJnPByM5rjbGJLK+ubMF3ATzIgDwBn5h/Kux1LcUZ14P0riPEQnttRt7uLGFXactgc9c0AdDp4aQAKCW757VoKuGGSTgYP1qjpTcOCVJCDaO3vitbZtQEjGRyMc5oAqOGOQp3D+6epzVW5tpldZEwueq9a0P3gldnTCgfLg5496kQZ+8OOQRjH40AZMUoZ13K27Pbgitq0vb2LLwzE4ACh+arTWgIYrjJGeKZEzRSDKsVXjFAGqmrXcnyug4z83rmpPOZxGSzbkPOP4qjtJIposptY44I7mrIQDH1/PigCjc3AjfzNr8/e9BWdeqJU+VxkjgHrite524x3I6Yqk8CNIrFRuQHDEdM9aAM62tzG6sdwX1Bz2q8swWQRsRk9CO4pNh2hQnTPyj+lIqoEyvO0fKT2oAseYNu5SCemDT/NyACpFUpVDwjzACevB6+1NE23OeDgcDmgAvXdtqmMMpbBK9RWbqSyYQROVC4HXAI9DVmW5KkuG6DJDVWnYZTk7vvYJ7UAc7rrCMlmTaVO4sDyBivL/EDJJFKZVKxsTsYdM9cEehr0rXnWaM9c4Pynt2Oa8/1v7PbxMJXwg5OGzjjrigDxq9XbdOHXp155z/AJ71DH5ahxJuxjClf51oa00Dzs8JZyWI3Dpn/Cs1CMtk/N/OgAXCyDB+YZ6ivcf2aZEXxPKBHvnaLgsOVHHNeHpuJwOc9q9K+BurHR/HdiLhmRLgGBt3TB6UAfc0R+QFsZIFJu3rlenvVSzkM9ujD7mMfWrcS7iNoxjpQBJGvynGcdRTntYpDuKAn3WpEULnoaeM44AoAXopwcn601s4znIAHAoYkqTjnHI/+vS4AHTmgAO4jBU/hSE8ncCOKCCMY4HoKUDGR29aAKt0SPu5x3rBms4zdySnLeZ8zKTwSBW3eZAAz17GsfUZzHAxUfM3HpQB594guFh1spG2yMfKu04AHqKyRNcXEcu5xFGrFGkx1x2H4d6ZrMbX2orFCUNw8uIz/dGcE59BRrlzFGgtoP4VMatz82epPuaAKghgMci2QAlJPLc5781o6dIVs/36AMexP6io7CNxak+SEK93PbHJq/ZW3mINwV4iNp3Jn+tAGnosbyag/wAqmNUA3qe/tXRTyRxW+3YBn1rOs0WxsgmUVRwoHpVOe83sCWAQcY96AMjx7YR6lpKB4xIsL72XGSQPT3p+nTQahYxxja8e0YX+lPlnZ3znAJwOfvVyFxNeaJfPJYp5kcznMbHAQ/7JoA0/FHgnTtUh+zDCROu1lQ/r9a562+FfhnR41uL+33Mh3byxKge4qWXUNZvb6F0kWSAuI5Gh6R/iOprfktNU1AJbrkW7Da0rAjjv1znj1xzQBkfDvVo7mW50qPJFu7mKQDgx7v0r0QWRmhkIRgo5JxT9C8O6bosIis4Ar7cFivzN35rojcPFb4xgAcgUAeW6p4Vtr64MlzErsW3Zbtx0rk/EXwXtNUf7TpU32WUkcBcg/hXrGqyr5yyYRkxv3buhHXisu01xbV5nQgcAhSeuc8igDwXUPgp4h06+GyS0urZjhmwQR7lTXtfwrsrjSfDlvpl23z22QCe9dVbeLbPUIIY5o4hKpCFe+adqBhW5kntF2RnquaAFupV3EYyfeuQ8TKboR2+AXllUZ/2Rya0NU1sQREuFHtnkVQ0BpNZ1D7dnFtGCsee5J5P9KANzTIACB2HQDj8a27aEjK54H8XXmorW2x8o5H1q9KywQmQngHHFAEP2Yn5mUAfXOaiaEqNxBOe3cVdsLkXkKyRo+D/eGKt+RuzngdCetAGKkTu37tST3o8rcxByQOM+ta62yHIDkN0BNVpocNwMDoaAMmC1FqStuPLUncQPX2q0kkpZSW3KB83XrTihVtpxjGeRmmRx+VCwJLc5PPPNAExYfeU7hjpjvUBYkHGOnXFMk3KMqCM9MGoxJgKr8fhQBI4UMrnqB6VWdg24FeAMelFxcBFZnIUdDmqU87rtaAblJAK7f1oAkeRlRQG+boM/xVR81kkGFPl/eIJ6N9O9WpXBzkAMDyKybiXZN98ZXseuPagAlnDSSu+0IR8ykd/aqc18UlDN8yNhMMeBngVU1CYw2zjO0E7lOePWqUsxDJkLskAHH880AN1C6jmdVXbkA7gGx9OnauD1a4hubWQoQU+ZXIGMsM1uXaG2llmVm2uDyegx/SuUvrtPsguY/m8zJ2qABnnigDzjVd6Bo3VQSTgj0z61m4J5Uda2de8tkUqZSVJ3BuRn2Pesm3U+YoAPJA46c0AOglaNWAAIPTAzg11Hw9gP/CV2FxeFooYZQzuVyBWzpfhOGRIZS2WUruCjPJ967i20yCHiGMegyOD60AfTHh28t7zSofsMyTrhfuNnH1reQBUwB04GK+Z/CupX/hvUUn06UiJiBJDn5WXPNfQ2gavBrVjHcWpwpGWQ9VPcGgDaXtnI/CnDkZDD8qjV92CCPTrUyj5R8tAEZPAU5AI6gd6MhiDyQOORSK2TntjAzTgCCeePTFADs4yTjB4xTWGf4RSDPzDGB2zRu478H+tAGfeyDeMHgDvWetstzOXbmMIQB6nFXb1S8hHPJwB9abMPIsn6fIh5zigDyjxALfSZppYldZJBsjA/gx94/Wub0mR77UYjKgVEHGBnHPc9qf4svWutY8vzQ6Kp4J6d+3vUfhuRm8wuQhGVBbk/lQB0UruVxG52ZG78+n1rZsQiIHZsKOx6muQt2a81PcScR7l27Tgjsf51sSXTNIsUW5gFGSOgNAGlPdKZP3jgIOmOg/8Ar1mT3WWKtgE5PA6e5rBk1LzjLDGVWZyypl+GYdarZktz5TXMIYrkgsdxznFAGxdajFbqzMwZh69q4/UdXuLqdd8UyWyEHdEQc88jHc1Rv7ppLhLaNsS4wHLHoevBOD0FS6P9uQtDIyLO8wj8sYDH0PsKAOk0e9a5LqmnPHZs20FMb2Y/xEZ4HvXe2VxDEsSzMIyxKhQ2c89a8/0mwubVvtUwkuZfMKPEj7RkHr9K66302DVbm2uI5xbmNtxRMfTGaAOksJ2uJzI4/dYK7mHzHB7e1SXN/GJCqKnmHhdzck/SjzIYYjbBmkZRgOncfh2rlpbq0l1RpYA24EmQs3CEDuO1AF+9WRy7RK1vMuNsmAVbHJX8RWXqdtGn7yTykaTGTtGSMdB70ltePPaTXFxOqK7GSEvkHAHTGenvVGVILu3iimC3Mm9ULx8bGJznrxigCGO2s1uvLjh8tRhhzwT3/KtJLGeeIiyv3G/kBxuGPaqqmEX00ciQyYIUOpAC9epPU5FbNooiiCgnPt6f4UAYyeGJ5rhW1C6ecDrGOARXU6bp0dnEqQoMAcAcAUQHK5OAuelW489VJHGcigC5alCCCpzkA461pCEONvYjIB/rWXEWdtwIOOCBx+Nalq7MhwhJ7YNAE1pEjgAZOFyNvAq4hKIANuGPHHT61FEMMUkBIB6e/vU2FC/JwBxQBTuI5ChAQB+u6qPzxxg3AG7GCR61q3O5jtXK+57is+5jCDnLOxyeO9AFOcqVJ6ZHJH09KryqVQgr1ABPrU0uARzhhk4qtuIiYKfmJ25oARgoUgEnuKqXSkjJ4GRk1LvCuct9ADUFxJlgADwOT2oArXSedC0TAsCMECqqkqDE+VwMjtx7Us867irnCt0Y1XMu7J6sRgk+v9KALEzbDjOR/TFZl6I2aLMeW5wTzj0q4rB0OfmP3SD0PrzUN2jtE3lEh1bOB069DQBgaiq4cSruXdg7f4eP8axZZNlusbMuFOFDcfMfU1t6uQA7qxynZT17Vz7MHnI6K2CAw6GgClqc6LG20FoiuFAHLMOn5/0rir+QJB9nkVT820Lg9GPPPtXbTozPHHG6qB8x7YPp+tY+qWbT/IjDJOVO0Ekg9if50AedaxsSFUVwIdu3afasDyh5hWEMR6j/AOtXWazaNDq8q3C7YHyuRjOcZH61irbFJUAIGDhxnAB96AO68AF/KE10zy5JSCFCS5OOv0ru5NKv5oYpLyUW8T8GKPhz9TUHwn0qK2t3vpwjOV2IpA+Ueua6/WvJngYo8e5Qckdf88UAYL6J/ZksMtq8ssAIVxI5IB+vpXo3w/vf7K1QQk4tLrg8dG7GsHw4ialpjxSYY9DuA59DVe1aayEiykk2xGGUcnHPA/CgD3y3O9c8jtx/WrAOQDurN0i8F7psE65XegJHvitCM4TG0n3FACnHXC9ccClHAX5c9+tIqgD0PcijOAVz9KAEGG9R3xnmlP3ST0xTsknsDjmmSHMfAxgdPWgCkq7piW55/Ks3xZP9l8P3spbbsjJBrWTCjpyea534jSBPCF7u/iKp0znJoA8CvNz3e5iBlBu75PWt6yKRRK5QJ8pXG7rjsax7fdHcKVP3Cd2R09jWnJIJbiGMICpbLYHIoAkhjla7aYzmO02HdGMguexJ9AKxvFmtz2Ph6/g08mGVRlZ0cMCvtjqfatbWdTi0y1ZmQ7RkDcQAyjrz3ry/xHBLqOhXNxCu5WYeXABt2AHt35z360AZ3hmTVL0R6kt9NJIzmN97YC+4xXfqzPbOJ5BNcuNm4nPT3rmfhxpd9ZaK0M0DLNNId6NgY9OPWvR7KxXbboi4Eac5AyDQBh2WjQ380CaoZjOjCQqq9R2GfSuvsNJVDu8hSwYsCeq1dEEUWJHG1nIyxOcVopOFX+HjBOe9AFeCB03BF6rnCr36Emqer29w8DxCNcFSMg7f5VtCQMrEEnHbuasQx+bkrkZOMZ60AcJpGqahpFs9rJb3E2M+UT6e59KqaVp95NNcM8csSzjEnctzn8q9OfQ1YgdhycdzVmLRUT5iQvsOtAHCf2FA0Un3uVCYOcR/T0pslrdWvmm3nVU2/IuzP/1zXoQ0+EbgMk4qjeaSVBZAD2zjmgDz+6ge6tZLnkSoF/cqv3sdsY61asnuIXfMqGcuMrtOE9vp71pzWbpKpkYGNG3bTnJPtWRHaGzvtQvgxKTR8A5+Ujt+NAHQRSyK6AqWyMli44/CtWCVGXIIyf0rz6wuriKyuPJDyXGRzu3KAcH8+vT0reW8kRokDMzOAAAOnrn2oA62JyjZB+cc8jr7Vu2cyKElY/eGOtc1azxNCrpt2kfy61q2joy9QAMHNAG/Goyuzuc565p87KAcZ2jmqkT+Yud+5uOB2NKrDhSDkcHHPT2oAmkc4OTjYRwT1HrXP+LddsNDsvtF7MFiU8knP5CtaSZdjZOBxxjNcl4x0e3162NtdoWhB5bH8jQA7S9Th1OyS5teYZBkZ7iryYwGY4Xrx61j6TDFplrFaQKRCgCr7CtQAbMHIYgED60AV7hGEczRgF8fKAOpqg+5Y2Mo5B5Pv3q1cPKVmibI2HKkDFZtwzxxt5jhwTge/HIFAFOcJv8AN3E4+cfNjIFZ13fRpDLK43legB6/lVjVIZVsA6/6xFYoo6cjofauWVpYyWdCZZlAeNuMZPJFAHRaRMGSK8MpFvKSxjYfdJq/cTsVZogrBvu5OOa5wQBbqKVpSYUbaqqePxqa4ujdLJHMjRrG+UceoGOKAINWuPN3J5m1s8AZ5z7Vz5lccBWOHJOc8CreoTbd7uCZCvByQOnSsuGdnJbJUv1Tv07GgB+oLmNAPMErEcgYJNVdRsbaZU+1q+wZ2d8eoyD19q2IUR1VpgQrc88n6e1VhaBPNcFiMH5SxIBoA8s1KxX7W6RSMqqdsZZjk+mfT1xRp0hm81L1YlK/P5rnBYg4rodat/szyRfZzJ5h3jbghyeDgew/nUUdi6iGZo1lkcYaFl647ZPHHWgDvvDSXSWVvDE++MHejL6ex6GtW9guQrOsZRfX3rH+HT3dxHHauzCO0dsHAJYdgD716pc6d51q+2PII6H1oA4PwtetYamokAWJ25z0z/8ArrsZ1Q3rhQCHGW44we9cLqdrNazSlUwUO5OcD8q6OO9MklpKvCyJzx1Pf8KAPU/Alwf7EjjYsSjFOvpXVr93p9eM1558O5lFxfRBs8hgT6H0r0BTxzgfhQBIc5HQ5GcZxQxYHBT8u1IAMAtjOOtLgkgcjPJPXFADUZRkZyc0kuAp/Ol3E5yBupk5BAzng/SgCMAA9KwPHqB/Dk3HG9eo/KuiAxjb9ayfFUP2jw9dR9Dtzu7jB7e9AHzzq8bxRi53sjbsYJHX04rSijmW3SWNWM54TcPTnk+lN1OzE10kKSySReWQSRzkE8+nPTNO1G/htLe2iZGeVs8Lwceozx+FAHM+JFN9dBbqMxrB/A5B2t6YHb61VsjAJvsdjHI6IQGZRtXJ6nJ9DWhfzpb3YuPNNxC4YbmYBiT3PsAO3rTbF2jsJRNDCiFssysdzfnQB0duUMUbw4Jjxkt97d2BNWJL2CGR414ZuRkfeP8AkVyM+tTsPLsAFiXCliPvdehosYLx3PmTCQdVB/pQB21vdfaLfejLvkTbszyrCrCXSsYw52M6YBJ4BHWuUM01vGEMJDEhuv3fcU7+0tuwSglsEMQeQaAO3ilTacbuBxk9fepU1ZkdFZCGJ7+tcdpuosZgm5gCMZb0+tbBmMsR2Pkg7QFAOTQB1w18RHyyD+J/lTv7bBKgnqcg56VyFwjSngYkUY9cURyyBMBdpBweKAPQbPUI5cs5G/HQd6nN7GCApGSOOa87+3PC4Z2aNAM4FWV1RFjB3435wxPNAHVXawSn5Noz97vXPXVsB/qiMMed3NQ/amiYEE425OTxmpba/DyIrYJIzjHBoAqQ6I32VljukQiRcPs+ZfwrPbUpY9RO2JmtIAQ56EHOBn19a3JoWuVk8ttqtjdk8/SsPVIriwtBDCs7MeRIsYIx6HNAGuLvyrtYIjtGOMj7+R1+lb+myE2vmk425BBwK4qUu4ttRupmkkRv3aIu3IxzjPWtWyuVS7ZCtwgzvJccMD/QUAdlYXT+W2cj5s8Hp+NaDuoUle+K5pbyNETAYhgcBea145gYUXPIA/CgCy0mANxy2f0rPkIkjkVsn1FTu4Rc5PTHWq826MfuiAc9W54oAr2wGxTIMEjnP6URTM2WKgLzhuoJzVa7upXjwmQAcAHvWRJ5rm1k80kQncxU9R9PSgDSnmWWEORjbuOM1iXdxHu+zs7KwQuW6YHTP15p8hkitWJkLuW+UHrg9qx9ZvZRbLthL3G3ax4Ax/8AroA04JYW07dHIznbhd3U1z8587VJSceXGQ+W4Pv+FUr25EVvbCHc2DucLkAfKefw4rLlu5JZk8xmLbCA8f8AHnqBQBsRxxSyMyksN+7b2BHIqC/lLBly2AflHXHrVfzTDazjLiQNtZRx83asfXtUO2G2Rx5pwXB6jNAC3t0POKjLKueW64/l1qW3KwW4dxsjA3lj2/CqDM28qwzzwoGQOK0ZbczWgicOVZOmcYP+NAGtpSC8sUudhCyZ2e4Hcj0p+rssNqpiBR2UkY455pIpBFpkMQY/J91Qf51Q1WKS6t1GBhhvO85z6igChcxSSKIyNjdSxPTuOazYbox+UroFdZApTltx7jPofXpUmoTLZW9upjGQc7VPDc9vT6VcsoC8ongyGDA/JwcY6c0AdZ4Kt72V5poUWK283KKFwT+Pb8K9E0+f7M6CZmxnDZ5rkvD96ILWQDC7W4x0HFWLe9kvJgI1OSeGJznmgA8b26G4cRYCMpPPPbNcpo16V0+0aVgwBIIHXAP8q6fxPcTDzw2MLHjdwAePSuM8LQ72iG0DncQxzigD2L4dSCTU7uSMfL5agkc5r0ce7KD7mvPvhrEqveybSAxCjHQfSu/Vsjoc0ATZ5wVyT1NPCryP4fSmkHOCSR6YpSOpHIHYCgAz82CRiopeqjmpDtULnoOg9KikIL9Sec8elAAMH1xVbVYhPp1zEmSGjYAd6uAHHGCDyabKuBhgMEUAeGSRqlxJJCMqilT3wevFYOstAbaSSeLfHGhQRqM789s9uK6LWILi3bVnmlBiXKxRHnbye49a891bUmhspFSRFIIyHbIAPX6n2oAybiKe6UPaCERxZCRZyy49fp6VXsLPUb+68q4lby8g7VGAwxgnit3TbeK7WNkRwQuF7FB36d61ZYTpJ2xAj91jJOW6dqAF0fTLe4jjRVRSvIGcE9sgVsWumyRKwXKsG+U9areCoFgjdyxy5wu/7wHpmu5trfepVVAHUk9BQBhWkSNgCJQ+7OWGf/1VZk0GyuG3XcSNI38Y4PPuK2ItPCygOmB1zjmrg05XkHlhyB1JXFAHHXPhm3t2lEDkFhgFxu2n2rMTTb8SYijTaHwGDYz74r0iTTJdhbYcDq3Sq5s5IwTsZew4xQBxogvwsjtbOoI2/fByfWpIZJ4wqzwTjPI4yfxxXWtFlAHA981CwjRt+wEA5yKAOW1WO6NtGZLZ0WTozckY7ECubluJLeaQTQyMU5VRg4/CvSbq7M2MKRt9B1rEv7VpWyyRqPUDmgDlrTUJLs/f8rYMlXHLD2qeG/jSeJzOYyOGQjrW7JY/aXVmhjIVQBtXB4pl1oCTxeY2GkByu3hh7/WgC9p99G6YBLKOSAasST/aIWiYKyEEKue9cLfWWpaPA15bqJIx975uozUGneIxqEaorNCWfcTj7pHb86APQ5I5JreNWiAaM7VYnjp/IVUvrs2+nS3NwxKJhScZwcgflVCwuZHLqbplPljIkwASR1FT3FtdW+jPboDOqjYp65B9aAN7T5InWKQRAKVAVh/h6VuW+RkseSD2rkdAtJIpAkVyzRRj5VYZx6jNdVBlF3N17E85oAlcYTIXn36VUeUKRkgE9+pxUzt8jcseT+P0rOu28uVTKw2Hjb6UAJPMIpkMwUqT8uOT71l3LqGcxgKM5xngL16VNqV1byeXsJPJVWXPWsWLUwtqZ7gGMYYGNvvbR2I9+tAEV6u+Z40by5lAkU9lP+NVboSRWTCKSOOJDvLP8xf8exyelZE15K8kkknyLNJuB9scZ9OBWcb6WSRbV5UkaNS7yAED2GKAEu7uV5xbKjShx9/oADwSfwqvI62twjQMqvGAAzDO0AdfyqpFLcQDDpmTzdueu5exqvOA0E9xcAiSQBBuOFOD/WgCVL8JaSzykKc5RcnLDtx+fNVra3eSb7bIFRjjDZ6jvn3qw8UYaMNEpIUNkDP+eTVTUrmeUPaqVQKCgZTkBu+cUAXrYhg7fe3HO70H9KvxmSPygjHDEswYZwKxdMu4rGOKCUoZHO1FPU1ftLyQsW2lY9+3JJ4OOMCgDTvI5JgEQKi4ILAckf0pbuUPDtDqipHgFRznp+NMgnEmWVgTH3Hf/CqF0C0zFCFDgEFe3PX+dAFGQJcNBHIyMI1G3OBu68/Wta0mc3W3ykA2cLnk/hWBDOXmaEMspLnLOB8v1x9a17O4ZSzh9+xtu1fTuOBQBt6bet5t3FIWQ+YRuboe3bpXU6EyrjKjIbOQOtZvhR9P1O2k8uNt8LESbhjNaM8BsSZojwP4TjGPpQBmeK7rLOq/ePBA53GqWjhbUKSyhypDDBIqnqN99v1NEiOCpwScgZ9K17aLhWYZHvwW+lAHrfw6gKaKJQAN7k81169OMVj+E7U2+iWiZyAgyO9baY2/eoAmZTkLgHA6E9KOOgBBAzkdDS8ZGAeepoB7MTigBB1wD+GKhmzuHIxzU5HbAGKilxxx8x6UACcjpz6+1MlJ64OOlSRgZ+U9e2OlMnyw2nigDyTxxEsct/H5oR5GJGeBnHY18/6xawf8JBsmWd13KPl5Qt/Tp1r6a8b2u+cOEDF4vMUADIKnHHrwa8G1YIdWbzP3bKjBQw+cNk5yBxyKAN7w5YO8+90RYhwirxwPXnntWvf266lapKh/excHcvLAVh6NqkNoEiQFYEUHzJM5LE9hXRO5Jf8AeNgd84wf8aAK2hYt7gJIAVJ42jB4969As5FkUAKcdef5V5vBexpqghYmKYHgnG189x/hXXaXdgRR/M4xycUAdlZkPKu4AsDkA961lgDMPL3Eenoa5qzvCGXftGOSa37a+Qx/IwBHbNAEt75cVuybnLMRtAPf3qmq4GJflYN36065kVmU5JzyKQTq+4kA5GOaAKstgkkUkzv8i5AXvVcaespRY0Dcng8Y9K1l8tdpbgjnAPWiWaFWLnncOucc+tAGcmkRtvkhKqVAGzHeo59Kha3klOwsrDKkdc96nuNYMY8tAMk/nisae/dnLAlS3PFADLmGOIKyqwIPzgjiq4O2aObcNmCSAPy/GiSdp5NsmWyckHvVV76OCJkcqSCcMxz096ALF9ax3umz2siEo3IHoD1rim8N6dp2XuEWRZsBdhxg9Dkir7as93chIpCcjACnGevGaWxsLiSRnmkbGMqp5APv24oAclhEXhigVuFG2RhvO3uM9vStFr54pZG8mVxGvGB989sdqkt7Qi3gZ2ChV5Cvjnpj+tUL57hUhSyyTG4DH0Hp70AbthBLDKsrOHVieg5Ga2t23K4GT1rMsJhLEGbP+6alnlfBEYAGR82e1AFpmI4I6jPJ61SuGVUyWBYnAx3pLiRkiZuijqTzWBqmou0SvbIEDMRt9R70AT6hdQwBUfAkk+6SO/rXJ3cqxJN50wkkmY7jno56Y+lWryc6pJE8jyx+WPnwcKV9cnrVSRLiS0d3iRZQ3DMByRjB4oAx2mZId4lVrfBVQeruO+P0rPnuIYpV8tQLh8ZOMAA4JFaepQGe0fKhcfcRcDHPJ9uKqtEiJJcCVkwgEjOeQPQAd6AIJ7x1vhEgjaMr5mUYcLx/+r61WeQTTIoykajEadcD1FT29tbNqSyLlYJV6yHqQeAMVHdslrqQdhicIzpL/dPfFAFi8RraytgQDKsgZ3I569h357Uy8tY57cOXPmS5duNrHPOfxrP1O7kFiJNrHncAx/L+lWPDiXDWsk965eWVsKSOh6dKAIo4I7uaJ2ZUGwgk4zj1/TPtVrT40knaI7v3CgMGGOT6evapZbIQSSeUVPmYTaRjp7980/TbeOJS8xbzVwpHvnqPXjigCoJxbTFEHUYbHOSDVm6aJIiVQ+YQPl6EetSajDbw7pGVipGOOc85z9KzbuVmLquM7Qxb6njFAFdoBExlTZuJ5A4yak0d5DcMFVWBbGNuMDB/Wql00hgIdflPB596fpcgeVgzeWBxktknGfyFAHT+AfESq08MkDKDKwIUff54zXZXOpxsoMihFOcqw614b4buZEvWkjmDEMWC4yc5rtVvbvU9ThEp+UHLsOB+dAD9Otb2CQ+ZbNHFI+9ZGbIb3+ntXb+GbSTVNTtbcHdJvBY9gP8APesubUYbVVtYcOSowo55Nel/C/R5bZHvrsETuNoTuPegD0GJFiUKhwqjAApd/pjFKqknLceooKgYxj8qALIPy56Z6Ck+YL2NHU8j6UuflX1oAQZJJwcmkcgDJyD2yOlKSeCSOnpQ2cHgZ9aAG5GRx2/Oo7jJ5IGcVIGUEZ9qjl+6MHNAHJ+MYwraXJtGC7xOx7KRXzv4wjez1q4mT5pYpmdXB2lgeNh3dvcdK+jfHI3eH4pBz5dwh5/GvC/ihZQX95HeSABjHtyWyrHnAx0yPegDktP1oX18DOWE/DLDgHGPlJ9hzXTi/jVhE2NxJJy3GP8AGuDj05RcAySATFQpUdhj/GrVrHe/aCIAZCjbR3BHrn6ZoA6zUGs9Tt5orjKsPu7Tkg+xrmp/Eur+F3T7TI19Zj7uT+8RfQ1sxaTPPtSdwhPVYgBtHua19P8ADlssab4Y5ZXO0MeSR3JP40AO8N/E/RdRgRJLsQTE8pJx+vSu6sNagl+eG4jZf4drA1wWofDfQbpJJZrRev3k+X8OKyF+GMUG06bqN5anjpLlc98ZoA9pTVd6hd3VSc56U06gURzvyc4XH8q8dHgvxXaOq2OvmVR089P51an074hW6kJLp18xPy7CyHHf6dDQB6xDqMnmIrnnvz1psl8d2Op6deleSJrPxAgmMT+HYnbHaUDj1p0178Q5YmlHh5Io15Y+aOPwBzQB6rcX8SoTxkHnFYmpa1bqikyqFB45xj1rzlrbxjdRGS8mit7dlBzGpYgE1q2Hg6KYhr+6lmbZuwx+Xt2oAtXniwTSqlgHlIyDsXj86barqGoyx+adkR/5Z46D3rpNN0m3tIDHFGqg84A68VowwqrA7drBeMigCjoGjJBcMztuGMYrbkt5FkRImwvVvcUkAAO5ThDnNEqbiX81weAFBx+FAGc1jDHdw4nkDhmkjQsSpPf+dYOoJdJc3Rt0WeMyqzc4CsOnPWtW41KCW9MKF/NiO3GMcn+lZn2y8tZJ3eKItIzI+BkD0x/j60Ablnfb4QgMYuOfkVu/pWlGW2I03BbjPvXmdvrMFg0d7a2UgeeQpmR8grnqM8cnP5V01r4jtrmFUdijlsAOcY+lAFzXtY+zI0KnaxHzA88E1gWpRI0hnfzSMnLdQTkj9DVXU7tjqPmzOsltKwVOcbePX3qFrRbu6BNzsDkMNnfHHWgCxfl5WZElHkyDCKnIQjn8un5Uy9VZUgCyn7OFAY5xz6n8adK/kv8AZVzFAEwZc5y5PSkmic2bybd/O7ahGW5oAybuVI5/LdBcfu9p2nBbJ7ehqxcwyvaCF40gDgRgkZI9B+nWqEEkkVy7s0KbzgMxH7vB5Aq3dSefMVUsIlcb3LfxD2/TFAFJkhRY2bISAHzFY4ye231rKvZRJGZ2Dlj/AAZ6DirVzdRSPcNKu90yEiBGVH94n6flVbTwLiQODldoKRsMfj/WgBs/zwrHdxj96xJ7YTHAx1zWppbva2axBd8784RPuqaRrZXZA4JKMWBznn1zWjaAwqxb5pfvfNwR6fhQBBBayQObq8dnm5KlukYPGB/WllU/u0ABVeQMY78f1q1PJcOCVGEkznaO1YOozEtEY5MtuyHUYCgen+BoAtzyypsAXcpbGD90Y7EVDdqSE7oADjHU9jmqay4DTyyZbPJzwAf61JPcK9upLZYPwCPyoAzr9zAm4KzKc4OckDrmqUdyFhumjJJSFyVB4yFOKZey+ZOzKGbknnofXis9Jmltb2EYR2hbp346CgDF8B6DqXiHVFt9NZogo3PMSQFGevv9K9jn+HusaeYiddE0b8NmA7l47dq7H9nPwMtt4Z+1X53yzHfGo6KvbmvXbnwtZ3TIZWbC9AvFAHkHgHwikOrBlaS8ue079Ez6DtXvGm2yWlssafeA5OOSfWo9OsLWwiEdpEEU9wOTVpT8x5oAcxDKMDnvSguRwRUN1cQWkRlup44Yx1Z2wK5ubx/4ZhlaM6tASpwdo3DP1oA6D7RsZTvOR/DSm4Kndu+Y+9cvJM2BhiCATnNSRXEjcsegxQB0f2hTk5HNIbhcHcfw/rWH5u4gk8H8KUuSeOvrQBqi+VSVLdM1Hc34EbdCawL0uEEg+VRw2aZFMxwCcjpQBU+Id6F8B3jsfmjljYH33CvCfF+pS3OkbcQmKOXfl03A5GPz969w8bWbX/grWLeNCzmAuqr1JXn+lfO2tK1z4dZULI23IwBlSOf6GgDk7YM96qPPLEF+9gglh6+ortI72OzjRI5AIolJZkbLDjofeuEjfLea0qtJ1MhJLbvw454q1duMQtGzBnH73DE5HNAHoOl6p9qAjidWjOPlA5JPcmuk029dJoj5ionAKsclV/xrzHQriNb0xDPmCPaSTXW20u2cbv3sjAZx/d//AF4oA7ptVhWQhpFODwC3X8Pxq/FqUMlxtjKEH5twIwK831BgpGeZG4ZcnAp0N4sGNkbfKMKue+OxoA9XttTjaQBSmCcANj8vrWpHd2uQjKMj5MDtmvDpdYihn/fuDJGMhSCoQ/Xua1NM8a28bxGY3LLg4YruEp+vtigD1m5tleSSSM5UjCrnkD1zTLW6lhZ0fO3sSM5GPWvOJvHggjJjgnZm5JCmkbxwZLfc8DnaAMLwAf60Aeh3f2V2ZVUjd97bXMahNDYF2hYnjAQtjj+tYlt4qe5jJW3liaRuSDy3pTBCtzc7r2T92F4DDOMe9AFm58QNHG5QbgDjgckY4psevT7/ALrh8A9MKKgv5LK3TzII97qOeNoArMa+SVN6rtdunONtAG+uv3H2gJKgjGzII5DH0z+NRanrjC8JaZlSBN2UOMMe/wDSuQ1TXxFIIYyG8w469D61i3t6J4JJJ5WilUEAqcjb9O9AHZ6jfJexRXMNyQ7ZRsnkcZySPoKoXXiEraRLLKgDfMSE4fAxz6c81w03mIClncyLCFywAycmmG8aaCETQTlgdin+9njmgDeWW3v4XCyusbTESKW+XOc5UHpz6Vak1FoeGxIkfQydV9hXIwTmJ7mJFRc9jnkn0p15dok8ayOvPRc5oA7qK4S4sVSSMnODhv4QPb61Db37AyRxsslsJMhl5/CsYaqsUUbkhiqgjP8ALNVo7ve4kVfLt+rBeBnp+JoA6b+1WuLkAoojizscNli3t/8AXqG81q6E3lXDP5SqGJVsA+mfwrMt7zFywjjXhej4yPwNVprn7XNLE80twRgERjhc/wAPp+NAHRuthII0OQ6MNojOfw9xzUV5ckmcQFo0VTtBPOen51k6fH5KD+B2YsV67eahjab7SsciBADuyGO0f7x/HpQA6WATwrJK21VAzIw4YjHB9fpW/pEIELmTa6zAZLL85YHt6AnAqtNJbNAkIKvHtzuXpk1et1a3WPDs02BuDA8E+9AGhFbyPDmaBULHcNrZKdwB/jUrWsm5ZXRySw47/j+dVI7sohIUyOGOCp5b8Kc99LuPkgp13KDz7kH8aALF+6rbDzJAGUkbRyBn2rCki3BnnBORjcB3/KklFxNctJJllBIC+2f5j1rQgRI41EgcqcgbiMk9e1AGVJaFFWXIKMckE45qpqc2wMqjLjBAb6dq1NRkJdgm0q3OMf1rn7qXZEw+ZtoyWXr3/SgDM1GcKi5PQHqOo65rP8PTebqzvyYwuSfSqesXocPGqq8jNkcYx/8AWq74f2W6MWjOXj+9gHJoA+zvhXOtz4Rs3h5XYBxjtXWXNxBawtLdTxwRqOWdgAK+MtC+M/iLQNJfQ9FgsoxGSqyupLe564rD8Q+J9f1pkbWb+W+Zh8qeZhVz/sigD6n8T/GbwlozPDDdPf3YO0R2ylhn/e6V5l4l+OWuXZli0q2isYvuh8bmHvn+leJ2ik31r5ivtLbj8v38e1aZOJftG0YlkIUhifp9aANi51rVNWufN1XU7iYspOJJTg/h2rMvLjyZv3sjq7gORHHwP84r1H4MeFJNe1iLWNTs91nCCI2kGPM9x2IFfQ/9jaVKAX062YjgExL0/KgDnV++v0P8hQfvj6UUUAWx1FO/jFFFAFbUP+PWb/dqlD94fUUUUAaS/wDHvP8A9c3/APQTXy3L/wAgu4/z3aiigDibj/kEWH/XI/0qxH/x4r/u0UUAWNM/4/b7/Peu5j/4+k+v9RRRQBFe/wDHxN/1z/rWOf8Aj7tf91v6UUUARa/9yT6Vp6F/x4ab9R/WiigDpJf9aPpWZL/x7p/vH+tFFAE2k/6xfqP51tfwSfQ/yoooAypv+PX/AIEaxpv9Uf8Arp/SiigDmL//AJCkf+7/AFpE/wBWfqP50UUAP0j/AFt1/wAC/nVi56/l/I0UUAYdh/x8vVDUf+QpRRQBq2v+pX/dFXE/goooA0pP+Pr/AIB/U1Jpn/ITf/gNFFAD7/8A5C8v/Xun9Kr6j1i+p/lRRQBY0j/jyg/31/ma6GX/AFp/66CiigBun9Lj61BD/rD/ANd2/kKKKALkff8A3mp8n8H+4P5UUUAY951j+ornbj/Xz/7/APQ0UUAcjff8fMv+4P51tad9yH/rmaKKAOXi/wCQvcf7z1qwf8hOX/rmtFFAGs/+pj/3v61eb/j1sf8Aruv86KKAPsXwJ/yALH/riv8AKuoh+4frRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retrobulbar hemorrhage causing dramatic proptosis and subconjunctival hemorrhage after a fist strike in a man on warfarin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36434=[""].join("\n");
var outline_f35_37_36434=null;
var title_f35_37_36435="Patient information: Medicines after an ischemic stroke (The Basics)";
var content_f35_37_36435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16238\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"         Tips on taking medicines",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/11/14515\">",
"         Patient information: Latest medicines to prevent blood clots (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/36/17986\">",
"         Patient information: Medicines for atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/54/40803\">",
"         Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/53/19286\">",
"         Patient information: Ischemic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines after an ischemic stroke (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicines-after-an-ischemic-stroke-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9352065\">",
"      <span class=\"h1\">",
"       What do the medicines prescribed after an ischemic stroke do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an ischemic stroke&mdash;a stroke caused by a blocked artery in the brain&mdash;the medicines your doctor prescribes afterward can help keep you from having another stroke. Your doctor might also prescribe these same medicines after a TIA (also called a &ldquo;mini-stroke&rdquo;). People who have TIAs are at very high risk of having a full-blown stroke, so medicines to prevent strokes are important for them, too. (TIA stands for &ldquo;transient ischemic attack.&rdquo;)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352072\">",
"      <span class=\"h1\">",
"       How do medicines help prevent strokes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some strokes happen when small arteries in the brain close off because they have been damaged by high blood pressure. Other strokes happen when blood clots form inside the heart or blood vessels and then travel to an artery in the brain. These blood clots just like the clots that stop the bleeding when you cut yourself. They are clumps of protein and blood cells that harden into a gel.",
"     </p>",
"     <p>",
"      Medicines that help prevent stroke work by reducing the chances that blood vessels will be damaged and by reducing the chances that clots will form.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352079\">",
"      <span class=\"h1\">",
"       Which medicines might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people who have had a stroke or TIA take 3 medicines or more. That may seem like a lot, but each of them does a different job.",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to prevent blood clots or &ldquo;thin&rdquo; the blood reduce the chance clots will form.",
"       </li>",
"       <li>",
"        Medicines that lower blood pressure help prevent the damage to blood vessels caused by high blood pressure. These medicines also help make sure the brain gets all the blood it needs.",
"       </li>",
"       <li>",
"        Medicines called statins lower cholesterol levels, especially the &ldquo;bad&rdquo; LDL cholesterol. They also help keep the arteries from getting damaged, which makes it less likely that clots will form in the first place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with other medical conditions, such as diabetes, need different medicines to treat those conditions as well.",
"     </p>",
"     <p>",
"      Whatever medicines your doctor prescribes, it's important that you take them exactly as directed (",
"      <a class=\"graphic graphic_table graphicRef59726 \" href=\"mobipreview.htm?32/6/32875\">",
"       table 1",
"      </a>",
"      ). If your medicines cause unwanted side effects or if you can&rsquo;t afford them, talk to your doctor or nurse. He or she might have ways to deal with these problems.",
"     </p>",
"     <p>",
"      This article has only some basic information on the main medicines used to prevent strokes. For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with other medicines or certain foods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352086\">",
"      <span class=\"h1\">",
"       Medicines to prevent blood clots",
"      </span>",
"      &nbsp;&mdash;&nbsp;When blood clots form inside the heart or blood vessels, they can travel to arteries in the brain and block the flow of blood. Medicines to prevent clots help keep this from happening. These medicines are especially important in people who have a heart condition called atrial fibrillation, because they are at high risk of forming clots.",
"     </p>",
"     <p>",
"      The most commonly used medicines to prevent blood clots are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         Aspirin",
"        </a>",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/11/21685?source=see_link\">",
"         Clopidogrel",
"        </a>",
"        (brand name: Plavix&reg;)",
"       </li>",
"       <li>",
"        A pill that contains",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        and another medicine called",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/43/23220?source=see_link\">",
"         dipyridamole",
"        </a>",
"        (brand name: Aggrenox&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/2/33830?source=see_link\">",
"         Warfarin",
"        </a>",
"        (brand name: Coumadin&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/58/933?source=see_link\">",
"         Dabigatran",
"        </a>",
"        (brand name: Pradaxa&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352093\">",
"      <span class=\"h1\">",
"       Medicines to lower blood pressure",
"      </span>",
"      &nbsp;&mdash;&nbsp;High blood pressure damages the walls of the arteries. This damage can cause small arteries in the brain to close off. It can also cause clots to form. Medicines that lower blood pressure help keep both these things from happening.",
"     </p>",
"     <p>",
"      There are lots of different medicines to lower blood pressure. Some people need more than 1 medicine to get their blood pressure low enough. The main medicines that doctors prescribe include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Diuretics (sometimes called &ldquo;water pills&rdquo;) &ndash;",
"        </strong>",
"        Some examples of diuretics include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/21/8533?source=see_link\">",
"         chlorthalidone",
"        </a>",
"        and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/20/10565?source=see_link\">",
"         hydrochlorothiazide",
"        </a>",
"        (also known as HCTZ).",
"       </li>",
"       <li>",
"        <strong>",
"         ACE inhibitors and ARBs &ndash;",
"        </strong>",
"        Angiotensin-converting enzyme inhibitors (called &ldquo;ACE inhibitors&rdquo;) and angiotensin receptor blockers (called &ldquo;ARBs&rdquo;) are often grouped together, because they work in similar ways. Some examples of ACE inhibitors include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30197?source=see_link\">",
"         enalapril",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/49/25365?source=see_link\">",
"         captopril",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/32/9734?source=see_link\">",
"         lisinopril",
"        </a>",
"        . Some examples of ARBs include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/50/4902?source=see_link\">",
"         candesartan",
"        </a>",
"        (brand name: Atacand&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/15/21749?source=see_link\">",
"         valsartan",
"        </a>",
"        (brand name: Diovan&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         Calcium channel blockers &ndash;",
"        </strong>",
"        Some examples of calcium channel blockers include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4309?source=see_link\">",
"         amlodipine",
"        </a>",
"        (brand name: Norvasc&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/12/1221?source=see_link\">",
"         felodipine",
"        </a>",
"        (brand name: Plendil&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/11/6326?source=see_link\">",
"         diltiazem",
"        </a>",
"        (brand name: Cardizem&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352100\">",
"      <span class=\"h1\">",
"       Statins",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have",
"      <strong>",
"      </strong>",
"      had an ischemic stroke often have fatty deposits inside their arteries called plaques. These plaques are made up mostly of cholesterol. Statins lower cholesterol, so they reduce the chances that plaques will form. They might also help shrink plaques and make them less likely to break open.",
"     </p>",
"     <p>",
"      Examples of statins include",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/47/6901?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (brand name: Lipitor&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/61/6101?source=see_link\">",
"       lovastatin",
"      </a>",
"      (brand names: Mevacor &reg;, Altoprev&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/21/37204?source=see_link\">",
"       pravastatin",
"      </a>",
"      (brand name: Pravachol&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/3/1077?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      (Crestor&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11541?source=see_link\">",
"       simvastatin",
"      </a>",
"      (Zocor&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9352197\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=see_link\">",
"       Patient information: Medicines for atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=see_link\">",
"       Patient information: Latest medicines to prevent blood clots (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       Patient information: Ischemic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"       Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/37/36435?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16238 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36435=[""].join("\n");
var outline_f35_37_36435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352065\">",
"      What do the medicines prescribed after an ischemic stroke do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352072\">",
"      How do medicines help prevent strokes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352079\">",
"      Which medicines might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352086\">",
"      Medicines to prevent blood clots",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352093\">",
"      Medicines to lower blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352100\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9352197\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"      Tips on taking medicines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36436="Diabetes mellitus type 2: Treatment";
var content_f35_37_36436=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/37/36436/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36436/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/37/36436/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36436/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/37/36436/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36436/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/37/36436?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Type 2 diabetes mellitus occurs when the pancreas (an organ in the abdomen) produces insufficient amounts of the hormone insulin",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the body becomes resistant to normal or even high levels of insulin. This causes high blood sugar (glucose) levels, which can lead to a number of complications if untreated.",
"    </p>",
"    <p>",
"     People with type 2 diabetes require regular monitoring and ongoing treatment to maintain normal or near-normal blood sugar levels. Treatment includes lifestyle adjustments, self-care measures, and medicines, which can minimize the risk of diabetes and cardiovascular (heart-related) complications.",
"    </p>",
"    <p>",
"     This topic review will discuss the treatment of type 2 diabetes. Topics that discuss other aspects of type 2 diabetes are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=see_link\">",
"      \"Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES TREATMENT GOALS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Blood sugar control",
"     </span>",
"     &nbsp;&mdash;&nbsp;The goal of treatment in type 2 diabetes is to keep blood sugar levels at normal or near-normal levels. Careful control of blood sugars can help prevent the long-term effects of poorly controlled blood sugar (diabetic complications of the eye, kidney, and cardiovascular system).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Home blood sugar testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with type 2 diabetes, home blood sugar testing might be recommended, especially in those who take oral diabetes medicines or insulin shots. Home blood sugar testing is not usually necessary for people who are diet-controlled. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A normal fasting blood sugar is less than 100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (5.6",
"     <span class=\"nowrap\">",
"      mmol/L),",
"     </span>",
"     although some people will have a different goal. Your doctor or nurse can help set your blood sugar goal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      A1C testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood sugar control can also be estimated with a blood test called A1C. The A1C blood test measures your average blood sugar level during the past two to three months. The goal A1C for most people with type 2 diabetes is 7 percent or less, which corresponds to an average blood sugar of 150",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"mobipreview.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ). For some people a higher HbA1c goal than this is safer and leads to better health outcomes. A healthcare provider can help determine your A1C goal.",
"    </p>",
"    <p>",
"     Your average blood sugar (150",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     is higher than your fasting blood sugar goal (100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 5.6",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     for several reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood sugar goes up after eating.",
"      </li>",
"      <li>",
"       How much and how fast your blood sugar goes up depends on the type and amount of food you eat at a particular meal.",
"      </li>",
"      <li>",
"       The amount your blood sugar goes up also depends on what diabetes treatment(s) you use and your activity level.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Cardiovascular risk control",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common long-term complication of type 2 diabetes is cardiovascular (heart) disease, which can lead to heart attack, chest pain, stroke, and even death. People with type 2 diabetes have twice the risk of heart disease as those without diabetes.",
"    </p>",
"    <p>",
"     However, you can substantially lower your risk of cardiovascular disease by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Quitting smoking",
"      </li>",
"      <li>",
"       Managing high blood pressure and high cholesterol with diet, exercise, and medicines",
"      </li>",
"      <li>",
"       Taking a low-dose aspirin (81 mg) every day, if indicated",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A detailed discussion of ways to prevent complications is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      DIET AND EXERCISE IN TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Changes in diet can improve many aspects of type 2 diabetes, including your weight, blood pressure, and your body's ability to produce and respond to insulin. Detailed information about type 2 diabetes and diet is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=see_link\">",
"      \"Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Regular exercise can help control type 2 diabetes, even if you do not lose weight. Exercise improves blood sugar control because it improves how your body responds to insulin. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES MEDICINES",
"     </span>",
"    </p>",
"    <p>",
"     A number of oral medicines (pills) are available to treat type 2 diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Metformin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who are newly diagnosed with type 2 diabetes will immediately begin a medicine called metformin (Glucophage&reg;, Gumetza&reg;, Riomet&reg;, Fortamet&reg;). Metformin improves how your body responds to insulin to reduce high blood sugar levels.",
"    </p>",
"    <p>",
"     Metformin is a pill that is usually started with the evening meal; a second dose may be added one to two weeks later (with breakfast). The dose may be increased every one to two weeks thereafter.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Common side effects of metformin include nausea, diarrhea, and gas. These are usually not severe, especially if you take metformin along with food.",
"    </p>",
"    <p>",
"     Patients with certain types of kidney, liver, and heart disease, and those who drink alcohol excessively should not take metformin. You should stop taking metformin 48 hours before any test that uses iodine-based contrast dye (like a CT scan with contrast), and you should stop it before any type of surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      When to add a second medicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your doctor or nurse might recommend a second medicine within the first two to three months if your blood sugar levels are still higher than your goal. Insulin shots might be recommended if your A1C is higher than 8.5 percent. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Which second medicine is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your blood sugar levels are still high after two to three months, but your A1C is close to the goal (between 7 and 8.5 percent), a second medicine might be added. The \"best\" second medicine depends upon individual factors, including the person's weight, other medical problems, and preferences regarding use of injections. The following are general recommendations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The most commonly recommended second medicine is a short acting sulfonylurea, such as glipizide&nbsp;(see",
"       <a class=\"local\" href=\"#H13\">",
"        'Sulfonylureas'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       A thiazolidinedione, such as pioglitazone, is an alternative to sulfonylureas, but only for people who are not at increased risk of heart failure or bone fracture (see",
"       <a class=\"local\" href=\"#H15\">",
"        'Thiazolidinediones'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       A GLP-agonist, such as exenatide, is an option for patients who are overweight and who want to avoid developing low blood sugar. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'GLP-agonists'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       A meglitinide, such as repaglinide, is an option for people who cannot take a sulfonylurea or prefer to avoid injections. (See",
"       <a class=\"local\" href=\"#H17\">",
"        'Meglitinides'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sulfonylureas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfonylureas have been used to treat type 2 diabetes for many years. They work by increasing the amount of insulin your body makes, and can lower blood sugar levels by approximately 20 percent. However, they stop working over time.",
"    </p>",
"    <p>",
"     Sulfonylureas are generally used if metformin does not adequately control blood sugar levels when taken alone. You should not take a sulfonylurea if you are allergic to sulfa drugs.",
"    </p>",
"    <p>",
"     A number of sulfonylureas are available (Diabinese&reg;, Orinase&reg;, Glucotrol&reg;, Diabeta&reg;, Micronase&reg;, Glynase&reg;, Amaryl&reg;), and the choice between them depends mainly upon cost and availability; they work similarly.",
"    </p>",
"    <p>",
"     If you take a sulfonylurea, you can develop low blood sugar, known as hypoglycemia. Low blood sugar symptoms can include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sweating",
"      </li>",
"      <li>",
"       Shaking",
"      </li>",
"      <li>",
"       Feeling hungry",
"      </li>",
"      <li>",
"       Feeling anxious",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Low blood sugar must be treated quickly by eating 10 to 15 grams of fast-acting carbohydrate (eg, fruit juice, hard candy, glucose tablets). It is possible to pass out if you do not treat low blood sugar fast enough. A full discussion of low blood sugar is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the past, insulin treatment was reserved for patients with type 2 diabetes whose blood sugars were not controlled with oral medicines and lifestyle changes. However, there is increasing evidence that using insulin at earlier stages may improve overall diabetes control and help to preserve the pancreas's ability to make insulin.",
"    </p>",
"    <p>",
"     Insulin injections may be used as a first-line treatment in some people with type 2 diabetes, or it can be added to or substituted for oral medicines. Insulin must be injected by the patient or a family",
"     <span class=\"nowrap\">",
"      member/friend.",
"     </span>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Thiazolidinediones",
"     </span>",
"     &nbsp;&mdash;&nbsp;This class of medicines includes pioglitazone (Actos&reg;), which work to lower blood sugar levels by increasing the body's sensitivity to insulin. They are taken in pill form and usually in combination with other medicines such as metformin, a sulfonylurea, or insulin.",
"    </p>",
"    <p>",
"     Common side effects of thiazolidinediones include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Weight gain and swelling of the feet and ankles.",
"      </li>",
"      <li>",
"       A small but serious increased risk of developing or worsening heart failure. An early sign of heart failure is swelling of the feet and ankles. People who take thiazolidinediones should monitor for swelling.",
"      </li>",
"      <li>",
"       A small but serious increased risk of developing fluid retention at the back of the eyes (macular edema).",
"      </li>",
"      <li>",
"       A small but serious increased risk of developing certain types of cancer (like bladder cancer).",
"      </li>",
"      <li>",
"       A small increased risk of bone fractures.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      GLP-agonists",
"     </span>",
"     &nbsp;&mdash;&nbsp;The GLP-agonists, Exenatide (Byetta&reg;) and liraglutide (Victoza), are injectable medicines. They are not a first-line treatment, but might be considered for people whose blood sugar is not controlled on the highest dose of one or two oral medicines. They may be especially helpful for overweight patients who are gaining weight on oral medicine.",
"    </p>",
"    <p>",
"     GLP-agonists do not usually cause low blood sugar. They promote weight loss, but can also cause bothersome side-effects, including nausea, vomiting, and diarrhea. Pancreatitis has been reported rarely in patients taking GLP-agonists, but it is not known if the drugs caused the pancreatitis. You should stop taking exenatide or liraglutide if you develop severe abdominal pain. Exenatide should not be used in patients with abnormal kidney function. These drugs are more expensive than insulin. Because they are relatively new drugs, long-term risks and benefits are not known.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27224657\">",
"     <span class=\"h2\">",
"      DPP-IV Inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;This class of medicines includes sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and vildagliptin (Galvus). Vildagliptin is available in Europe but not in the United States. They lower blood sugar levels by increasing insulin release from the pancreas in response to a meal. They are not a first-line treatment, but they can be given alone in patients who can&rsquo;t tolerate the first-line medicines (metformin, sulfonylureas), or they can be given with other oral medicines if blood sugars are still higher than goal. These medicines do not cause hypoglycemia or changes in body weight. However, they may cause some nausea and diarrhea. There have been rare reports of pancreatitis and skin reactions. DPP-IV inhibitors are expensive, and the long-term risks and benefits are unknown.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Meglitinides",
"     </span>",
"     &nbsp;&mdash;&nbsp;Meglitinides include repaglinide (Prandin&reg;) and nateglinide (Starlix&reg;). They work to lower blood sugar levels, similar to the sulfonylureas, and might be recommended in people who are allergic to sulfa-based drugs. They are taken in pill form. Meglitinides are not generally used as a first-line treatment because they are more expensive than sulfonylureas and are short-acting, so they must be taken with each meal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Alpha-glucosidase inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;These medicines, which include acarbose (Precose&reg;) and miglitol (Glyset&reg;), work by interfering with the absorption of carbohydrates in the intestines. This helps to lower blood sugar levels, but not as well as metformin or the sulfonylureas. They can be combined with other medicines if the first medicine does not lower blood sugar levels enough.",
"    </p>",
"    <p>",
"     The main side effects of alpha-glucosidase inhibitors are gas (flatulence), diarrhea, and abdominal pain; starting with a low dose may minimize these side effects. The medicine is usually taken three times per day with the first bite of each meal.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      LIVING WITH TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     People with type 2 diabetes often feel stress related to their disease and the increased responsibilities that come with diabetes, including blood sugar testing, watching the diet, exercise, doctor visits, the need for medicines, and the potential risks of complications. It is not uncommon to become depressed as a result of this stress, and this can make taking care of yourself more difficult.",
"    </p>",
"    <p>",
"     Committing to new treatments and lifestyle changes can be difficult, and it is not uncommon to feel that the benefits of treatment are not worth the effort. Having an open and honest discussion with a doctor or nurse can help you to understand your diagnosis and the need for treatment.",
"    </p>",
"    <p>",
"     Involving family and friends can help you to manage your disease by offering reminders to take medicine, test blood sugar levels, and providing a ride to appointments. Family and friends can also give encouragement and support to eat a healthy diet and stick with an exercise plan.",
"    </p>",
"    <p>",
"     Working with a psychotherapist or social worker can help you cope with new responsibilities and worries. A number of studies have shown that people who have psychotherapy in addition to traditional medical care have reduced stress and improved blood sugar control compared with people who received only traditional care [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/37/36436/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804466987\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18610643\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=see_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38114?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/42/35490?source=see_link\">",
"      Patient information: Counting carbs if you do not use insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/25/15763?source=see_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25699?source=see_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18610651\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/28/18886?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=see_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Diabetes Associates",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.ca/\">",
"      www.diabetes.ca",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/diabetes\">",
"      www.cdc.gov/diabetes",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/37/36436/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/37/36436?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36436/abstract/1\">",
"      Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36436/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36436/abstract/3\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36436/abstract/4\">",
"      Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117:762.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_37_36436=[""].join("\n");
var outline_f35_37_36436=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TYPE 2 DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPE 2 DIABETES TREATMENT GOALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           DIET AND EXERCISE IN TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPE 2 DIABETES MEDICINES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           LIVING WITH TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36437="Metoprolol and hydrochlorothiazide: Patient drug information";
var content_f35_37_36437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metoprolol and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/27/31159?source=see_link\">",
"     see \"Metoprolol and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1698647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dutoprol&trade;;",
"     </li>",
"     <li>",
"      Lopressor HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metoprolol, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11349 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36437=[""].join("\n");
var outline_f35_37_36437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698647\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019938\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019940\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019939\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019944\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019945\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019947\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019942\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019943\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019948\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019949\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/27/31159?source=related_link\">",
"      Metoprolol and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36438="Invasive beta catenin";
var content_f35_37_36438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advancing (invasive) edge of a gastric adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Strongly positive nuclear strain of beta-catenin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36438=[""].join("\n");
var outline_f35_37_36438=null;
var title_f35_37_36439="Differential diagnosis of transient ischemic attack and stroke";
var content_f35_37_36439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of transient ischemic attack and stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     Louis R Caplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36439/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/37/36439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of brain ischemia may be transient, lasting seconds to minutes, or can persist for longer periods of time. Symptoms and signs remain indefinitely if the brain becomes irreversibly damaged and infarction occurs. Unfortunately, neurologic symptoms do not accurately reflect the presence or absence of infarction, and the tempo of the symptoms does not indicate the cause of the ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This is a critical issue because treatment depends upon accurately identifying the cause of symptoms, and the nature, location, and severity of causative cardiac, hematologic, and cerebrovascular abnormalities.",
"   </p>",
"   <p>",
"    The differential diagnosis of transient ischemic attack and stroke will be reviewed here. The evaluation of stroke and transient cerebral ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSIENT ISCHEMIC ATTACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attack (TIA) is defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. In keeping with this definition of TIA, ischemic stroke is defined as an infarction of central nervous system tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"transient ischemic attack\" was first introduced in the early 1950s based upon the recognition that a transient focal loss of neurologic function often preceded strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/3\">",
"     3",
"    </a>",
"    ]. In the years after this initial description in patients with carotid artery disease, various groups and committees arbitrarily defined TIAs as lasting less than 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/2\">",
"     2",
"    </a>",
"    ]. However, this classic definition of TIA was inadequate for several reasons. Most notably, there is risk of permanent tissue injury (ie, infarction) even when focal transient neurologic symptoms last less than one hour.",
"   </p>",
"   <p>",
"    Subsequent data demonstrated that ischemic attacks that last longer than one hour are most often associated with brain infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Most TIAs last less than one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the benign connotation of TIA has been replaced by an understanding that even relatively brief ischemia can cause permanent brain injury.",
"   </p>",
"   <p>",
"    The definition of TIA is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms of TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attacks are caused by decreased blood flow to a local portion of the brain. Decreased perfusion can be due to blockage of blood flow to a brain region from an in-situ occlusion of a supply artery, or from embolism to that artery. Symptoms are",
"    <strong>",
"     focal",
"    </strong>",
"    , suggesting that they relate to dysfunction of a localized area of the brain. Symptoms are also",
"    <strong>",
"     transient",
"    </strong>",
"    when the arterial blockage passes (eg, following dissolution or distal passage of an embolus) or when collateral circulation is able to restore adequate perfusion to the region of ischemia. The symptoms and signs may fluctuate depending upon the adequacy of perfusion, which is in turn related to systemic factors (eg, blood volume, cardiac output, blood pressure, blood viscosity) and local factors (eg, propagation and embolization of clot, development of collateral circulation).",
"   </p>",
"   <p>",
"    The symptoms of TIAs depend upon the underlying vascular cause (",
"    <a class=\"graphic graphic_table graphicRef71676 \" href=\"mobipreview.htm?6/47/6910\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/6\">",
"     6",
"    </a>",
"    ]. When ischemia is caused by penetrating artery disease, for example, the symptoms are usually stereotyped (eg, numbness of the face, arm, and leg on one side of the body, or hemiparesis). In contrast, attacks due to large artery occlusive disease have different symptoms in different attacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the carotid artery is narrowed or occluded, patients may have monocular blindness on the side of the occlusive lesion, weakness of the contralateral hand, or aphasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occlusive lesions of the internal carotid artery in the neck or head, or of its major intracranial branches, the middle and anterior cerebral arteries, cause loss of cerebral hemisphere functions.",
"     </li>",
"     <li>",
"      Occlusive lesions of the vertebral arteries in the head and neck and of the basilar artery cause brainstem and cerebellar symptoms and deficits.",
"     </li>",
"     <li>",
"      Occlusive disease of the posterior cerebral arteries (PCAs) causes visual and somatosensory symptoms due to loss of function in the lateral thalamus and occipital lobe regions supplied by the PCAs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, some TIAs, such as those causing transient monocular blindness, diplopia, and aphasia, are very specific for one vascular territory, while others, such as limb weakness or numbness, are compatible with a number of different territories.",
"   </p>",
"   <p>",
"    The occurrence of a TIA is not helpful in predicting the presence of brain damage, the cause and mechanism of the ischemia, or the prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Transient brain ischemia can be caused by a variety of different conditions (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40678?source=see_link\">",
"     \"Etiology and clinical manifestations of transient ischemic attack\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain embolism arising from the heart, aorta, or proximal arterial vessels.",
"     </li>",
"     <li>",
"      Occlusive lesions of either large extracranial or intracranial arteries. These large artery lesions are associated with intermittent hypoperfusion of the symptomatic regions of the brain, or with embolization of fibrin-platelet (white thrombi) or erythrocyte-fibrin (red thrombi) clots into the distal brain circulation. Emboli often break up or pass through the vasculature, explaining the transiency of the neurologic symptoms.",
"     </li>",
"     <li>",
"      Occlusive lesions (either lipohyalinosis or atheromatous branch disease) of small microscopic-sized intracranial arteries and arterioles.",
"     </li>",
"     <li>",
"      Hypercoagulability and diseases that cause thrombosis of small vessels (eg, thrombotic thrombocytopenic purpura).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSIENT NEUROLOGIC EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of TIAs includes all other causes of transient \"spells\". The Australians often use the nonspecific word \"turns\" for such transient episodes of neurologic dysfunction.",
"   </p>",
"   <p>",
"    In addition to TIAs, the most important and frequent causes of discrete self-limited attacks include (",
"    <a class=\"graphic graphic_table graphicRef71722 \" href=\"mobipreview.htm?22/25/22940\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Migraine aura",
"     </li>",
"     <li>",
"      Syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some disorders mentioned above cause focal abnormalities of brain function, while others cause dysfunction that is either widespread or difficult to localize to any one anatomic region (",
"    <a class=\"graphic graphic_table graphicRef62326 \" href=\"mobipreview.htm?7/21/7516\">",
"     table 3",
"    </a>",
"    ). Certain disorders may also cause both focal and nonfocal attacks. Seizures, for example, can begin and remain focal or can be generalized. Similarly, patients with hypoglycemia usually have global deficits in alertness and cognition, but on occasion can have focal symptoms such as hemiplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"transient neurological attack\" (TNA) has been proposed to describe sudden neurologic symptoms that completely resolve within 24 hours, with no clear evidence to support a diagnosis of migraine, epilepsy, M&eacute;ni&egrave;re disease, hyperventilation, cardiac syncope, hypoglycemia, or orthostatic hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/8\">",
"     8",
"    </a>",
"    ]. The symptoms of TNAs can be focal, nonfocal, or mixed. In this classification, focal TNAs represent TIAs, while TNAs with nonfocal or mixed symptoms are heterogeneous in terms of etiology. Like TIAs, both nonfocal and mixed TNAs appear to be associated with an increased risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An epileptic seizure refers to a transient occurrence of signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms due to abnormally excessive neuronal activity of the brain. Seizures, especially repeated focal seizures, can be followed by postictal paralysis or loss of other functions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the first seizure in adults\", section on 'Postictal state'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Nonepileptic seizures are characterized by sudden changes in behavior that resemble epileptic seizures but are not associated with the typical neurophysiological changes that characterize epileptic seizures.",
"   </p>",
"   <p>",
"    The symptoms of seizures and nonepileptic paroxysmal events are diverse. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of the first seizure in adults\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Migraine aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine aura is the complex of neurologic symptoms that often accompanies migraine headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H203275055#H203275055\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An aura presents as a progressive neurologic deficit or disturbance with subsequent complete recovery. Auras are thought to be caused by cortical spreading depression occurring in regions of the cortex that correspond to the clinical manifestations of the aura.",
"   </p>",
"   <p>",
"    Auras typically occur before the onset of migraine headache, and the headache usually begins simultaneously with or just after the end of the aura phase. However, headache onset can rarely occur an hour or more after the end of the aura phase. Although atypical, an aura can develop during or after the onset of headache, and many patients have migraine aura with only a minimal or no headache.",
"   </p>",
"   <p>",
"    Most migraine auras resolve in 20 to 30 minutes and seldom last more than one hour. Typical auras may involve any of the following manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Visual disturbances",
"     </li>",
"     <li>",
"      Sensory symptoms",
"     </li>",
"     <li>",
"      Motor weakness",
"     </li>",
"     <li>",
"      Speech disturbances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visual disturbances are the most common type of aura.",
"   </p>",
"   <p>",
"    The relationship between migraine and ischemic stroke is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link\">",
"     \"Headache, migraine, and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is the abrupt and transient loss of consciousness associated with absence of postural tone, followed by a rapid and usually complete recovery. Syncope is caused by an interruption of energy sources to the brain, usually because of a sudden reduction of cerebral perfusion.",
"   </p>",
"   <p>",
"    Common types of syncope include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurocardiogenic (vasovagal) syncope",
"     </li>",
"     <li>",
"      Situational syncope (during or immediately after urination, defecation, cough, or swallowing)",
"     </li>",
"     <li>",
"      Orthostatic syncope (associated with orthostatic hypotension)",
"     </li>",
"     <li>",
"      Syncope related to cardiac ischemia or cardiac arrhythmia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transient global amnesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient global amnesia (TGA) is reviewed here and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38328?source=see_link\">",
"     \"Transient global amnesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, TGA is a syndrome characterized by the acute onset of severe anterograde amnesia accompanied by retrograde amnesia, without other cognitive or focal neurologic impairment. The amnesia resolves within 24 hours. Most patients are middle aged or older adults. Episodes are usually not recurrent, but rare patients have infrequent attacks that recur over several years.",
"   </p>",
"   <p>",
"    The etiology of TGA is uncertain. Most TGA episodes are probably related to vasoconstriction, but some may be caused by transient ischemia or complex partial seizures. TGA can be associated with small focal abnormalities on diffusion-weighted MRI, but the significance of these remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less frequent causes of transient neurologic events include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic perturbations, such as hypoglycemia, can be associated with focal neurologic deficits.",
"     </li>",
"     <li>",
"      Multiple sclerosis occasionally can cause paroxysmal attacks, particularly of ataxia and dysarthria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H22#H22\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Paroxysmal symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain tumors can occasionally result in transient neurologic symptoms; the mechanism in these cases is thought to involve mechanical changes that result in pressure on structures adjacent to the tumor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subdural hematomas may cause attacks of transient neurologic dysfunction, again due to mechanical changes that result in pressure on structures adjacent to the hematoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=see_link\">",
"       \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebral amyloid angiopathy, better known as a cause of intracerebral hemorrhage, may also cause transient neurologic symptoms. Affected patients complain of recurrent, brief (minutes), often stereotyped spells of weakness, numbness, paresthesias, or other cortical symptoms that can spread smoothly over contiguous body parts. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=see_link&amp;anchor=H10#H10\">",
"       \"Cerebral amyloid angiopathy\", section on 'Transient neurologic symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatic, renal, and pulmonary encephalopathies can produce temporary aberrations in alertness, behavior and movement.",
"     </li>",
"     <li>",
"      Compressive myelopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/9\">",
"       9",
"      </a>",
"      ] and spinal dural arteriovenous fistulas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/10,11\">",
"       10,11",
"      </a>",
"      ] may occasionally present with sudden transient sensory changes and motor deficits, especially in the bilateral lower limbs.",
"     </li>",
"     <li>",
"      Pressure- or position-related peripheral nerve or nerve root compression can cause transient paresthesias and numbness.",
"     </li>",
"     <li>",
"      Peripheral vestibulopathies can cause transient episodic dizziness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=see_link\">",
"       \"Approach to the patient with dizziness\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"       \"Approach to the patient with vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hysteria and other psychiatric disorders may underlie attacks that include swoons, falls, and episodic blindness, deafness, and paralysis, which can be confused with organic loss of function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISTINGUISHING TRANSIENT ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is important in distinguishing the various causes of transient attacks. Useful historical features include (",
"    <a class=\"graphic graphic_table graphicRef71722 \" href=\"mobipreview.htm?22/25/22940\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The focal or nonfocal nature of attacks",
"     </li>",
"     <li>",
"      The nature of the symptoms and their progression",
"     </li>",
"     <li>",
"      The duration and timing of symptoms",
"     </li>",
"     <li>",
"      Associated symptoms during and after the attacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nature of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms can be categorized using Jacksonian terminology as either \"positive\" or \"negative.\"",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive symptoms indicate active discharge from central nervous system neurons. Typical positive symptoms can be visual (eg, bright lines, shapes, objects), auditory (eg, tinnitus, noises, music), somatosensory (eg, burning, pain, paresthesia), or motor (eg, jerking or repetitive rhythmic movements).",
"     </li>",
"     <li>",
"      Negative symptoms indicate an absence or loss of function, such as loss of vision, hearing, feeling, or ability to move a part of the body.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures and migraine auras characteristically (but not always) begin with positive symptoms, while TIAs invariably are characterized by negative symptoms. Seizures occasionally cause paralytic attacks but, on close observation, there are usually features of the history and physical examination that suggest the presence of a seizure disorder such as minor twitching of a finger or toe or a tingling sensation in the affected limb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Progression and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progression and course of the symptoms are also helpful in the differential diagnosis. Migraine aura often progresses slowly within one modality. As an example, scintillations or bright objects tend to move slowly across the visual field. Paresthesia may gradually progress from one finger, to all the digits, to the wrist, forearm, shoulder, trunk, and then the face and leg. This progression normally occurs over minutes. After the positive symptoms move, they are often followed by loss of function. The moving train of visual scintillations may end in a scotoma or visual field defect. Similarly, as paresthesia travel centripetally, they may leave the initial areas of skin numb and devoid of feeling.",
"   </p>",
"   <p>",
"    Migrainous aura typically progresses from one modality to another; after the visual symptoms clear, paresthesia begins. When paresthesia clear, aphasia or other cortical function abnormalities may develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to migraine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizures usually consist of positive phenomena in one modality which progress very quickly during seconds.",
"     </li>",
"     <li>",
"      TIA symptoms are negative; when more than one modality or function is involved, all are affected at about the same time.",
"     </li>",
"     <li>",
"      Loss of consciousness is very common in seizures and syncope, which usually produce relatively stereotyped attacks; in comparison, loss of consciousness is extremely rare in TIAs, and symptoms can be stereotyped or different in various TIAs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration and tempo",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration and tempo of attacks also are useful in predicting the cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migrainous auras characteristically last 20 to 30 minutes, although they may persist for hours",
"     </li>",
"     <li>",
"      TIAs are usually fleeting, almost always lasting less than one hour",
"     </li>",
"     <li>",
"      Seizures last on average about 30 seconds to 3 minutes; some seizures, including absence attacks, atonic seizures and myoclonic jerks, are shorter in duration",
"     </li>",
"     <li>",
"      Syncope is very brief (seconds) unless the patient is artificially propped up or otherwise cannot obtain a supine position",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures occur sporadically over the years but sometimes appear in flurries. In comparison, TIAs usually cluster during a finite period of time and can occur as frequent \"shotgun\"-like attacks, and syncopal attacks are scattered over years. Attacks that are scattered over many years are almost always either faints, migraines, or seizures; TIAs almost never continue over this time span.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitants often give clues to the cause of attacks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of seizures is well known to occur in some patients after stroboscopic stimulation, hyperventilation, reading, cessation of anticonvulsants, fever, and alcohol or drug withdrawal.",
"     </li>",
"     <li>",
"      In some patients, TIAs occur when blood pressure is reduced, or upon sudden standing or bending.",
"     </li>",
"     <li>",
"      Dizziness and vertigo in patients with peripheral vestibulopathies are often triggered by sudden movements and positional changes.",
"     </li>",
"     <li>",
"      Syncope commonly occurs when patients see blood, have or are about to have phlebotomy or other medical procedures, see an electric saw poised to remove a plaster cast on their arm or leg, stand up for a long time in church, or when a dental drill is aimed directly at their open mouth by a dentist. Hypovolemia also frequently precipitates syncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-neurologic associated symptoms can be characteristic of certain disorders. Headache is common after migraine aura and following a seizure. Headache can also occur during a TIA, but rarely at the same time or directly after neurologic symptoms.",
"   </p>",
"   <p>",
"    A bitten tongue, incontinence, and muscle aches are frequently associated with seizure. Vomiting is common after migraine and occasionally follows syncope, but is extremely rare after or during TIA and in relation to seizure. In the latter circumstance, vomiting may develop after the patient has lost consciousness; patients do not recall vomiting unless they see the vomitus when they awaken. Nausea and a need to urinate or defecate often precede or follow syncope; sweating and pallor are other common features of syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patient age and gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demography may be helpful but there is substantial overlap (",
"    <a class=\"graphic graphic_table graphicRef71722 \" href=\"mobipreview.htm?22/25/22940\">",
"     table 2",
"    </a>",
"    ). Seizures occur at any age, while TIAs are not very common in young individuals, particularly those who do not have prominent risk factors for vascular disease (eg, hypertension, diabetes, smoking, cardiac disease, sickle cell disease, etc). In otherwise healthy women who are pregnant, transient focal neurologic symptoms are often related to migraine with aura, and usually have a benign outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36439/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syncope has little predilection for age, but is more common in women. TIAs and strokes are somewhat more common in men, although after menopause the frequencies are nearly equal in the two sexes. Seizures have no strong sex predilection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PERSISTENT NEUROLOGIC DEFICITS WITH ABRUPT ONSET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic strokes are characterized by the abrupt or at least very acute onset of focal neurologic symptoms and signs that leave persistent neurologic deficits. Other disorders that have acute onset and cause persistent focal signs should be considered in the differential diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracerebral hemorrhages usually develop during minutes and cause gradually increasing focal signs. Patients with large hemorrhages often develop headache, vomiting, and reduced consciousness; these findings are typically absent in patients with small hemorrhages. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"       \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain tumors can cause an abrupt onset or worsening of symptoms; hemorrhage into a tumor is one mechanism for such a change. In addition, some tumors which are outside the brain (eg, meningiomas) reach a critical mass and can cause abrupt displacement of brain tissue with the sudden onset of symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonketotic hyperglycemic stupor is often associated with focal neurologic signs; there may be a focal region of brain edema on brain imaging tests. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attacks of multiple sclerosis can begin abruptly and may have paroxysmal transient attacks as discussed above (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Other causes'",
"      </a>",
"      above). Most often however, MS attacks develop over 5 to 21 days, a longer period than strokes. MS is most common in the third to fifth decades of life, while the frequency of stroke peaks later. A history of prior attacks is very important in making the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Demyelination can occur around veins after various viral infections which result in the abrupt onset of multifocal signs that develop over days. This disorder is often called acute disseminated encephalomyelitis (ADEM). Other viral infections, particularly cytomegalovirus, can cause focal brain lesions associated with focal neurologic signs.",
"     </li>",
"     <li>",
"      Brain abscesses cause focal neurologic symptoms and signs which can begin abruptly; fever, headache, and seizures are common accompanying signs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54661373\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient ischemic attack (TIA) is defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. Ischemic stroke is defined as an infarction of central nervous system tissue. The symptoms of TIAs are typically focal and depend upon the underlying vascular cause (",
"      <a class=\"graphic graphic_table graphicRef71676 \" href=\"mobipreview.htm?6/47/6910\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transient ischemic attack'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to TIA, the most important and frequent causes of discrete self-limited attacks include seizure, migraine aura, and syncope (",
"      <a class=\"graphic graphic_table graphicRef71722 \" href=\"mobipreview.htm?22/25/22940\">",
"       table 2",
"      </a>",
"      ). Transient global amnesia or TGA is an uncommon syndrome characterized by the acute onset of temporary but severe anterograde amnesia accompanied by retrograde amnesia, without other cognitive or focal neurologic impairment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transient neurologic events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other less frequent causes of transient neurologic events include hypoglycemia, multiple sclerosis, brain tumor, subdural hematoma, cerebral amyloid angiopathy, various toxic or metabolic encephalopathies, compressive myelopathy, nerve root compression, peripheral vestibulopathies, and psychogenic etiologies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Useful features for distinguishing the various causes of transient attacks include the focal or nonfocal nature of attacks, the nature of the symptoms and their progression, the duration and timing of symptoms, and associated symptoms during and after the attacks (",
"      <a class=\"graphic graphic_table graphicRef71722 \" href=\"mobipreview.htm?22/25/22940\">",
"       table 2",
"      </a>",
"      ). Some disorders cause focal abnormalities of brain function, while others cause dysfunction that is either widespread or difficult to localize to any one anatomic region (",
"      <a class=\"graphic graphic_table graphicRef62326 \" href=\"mobipreview.htm?7/21/7516\">",
"       table 3",
"      </a>",
"      ). Certain disorders may cause both focal and nonfocal attacks. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Distinguishing transient attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic stroke is characterized by the abrupt or at least very acute onset of focal neurologic symptoms and signs that leave persistent neurologic deficits. Other disorders that have acute onset and cause persistent focal signs should be considered in the differential diagnosis, including intracerebral hemorrhage, brain tumor, nonketotic hyperglycemic stupor, attacks of multiple sclerosis, acute disseminated encephalomyelitis, and brain abscess. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Persistent neurologic deficits with abrupt onset'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/1\">",
"      Caplan LR. TIAs: we need to return to the question, 'What is wrong with Mr. Jones?'. Neurology 1988; 38:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/2\">",
"      Caplan LR. Transient ischemic attack: definition and natural history. Curr Atheroscler Rep 2006; 8:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/3\">",
"      FISHER M. Occlusion of the internal carotid artery. AMA Arch Neurol Psychiatry 1951; 65:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/4\">",
"      Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack--proposal for a new definition. N Engl J Med 2002; 347:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/5\">",
"      Caplan LR. Transient ischemic attack with abnormal diffusion-weighted imaging results: what's in a name? Arch Neurol 2007; 64:1080.",
"     </a>",
"    </li>",
"    <li>",
"     Kumar, S, Caplan, LR. Clinical syndromes &mdash; brain. In: Transient ischemic attacks, 1st ed, Chaturvedi, S, Levine, SR (Eds), Blackwell Publishing, Malden 2004. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/7\">",
"      MONTGOMERY BM, PINNER CA. TRANSIENT HYPOGLYCEMIC HEMIPLEGIA. Arch Intern Med 1964; 114:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/8\">",
"      Bos MJ, van Rijn MJ, Witteman JC, et al. Incidence and prognosis of transient neurological attacks. JAMA 2007; 298:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/9\">",
"      Cochrane T, Schmahmann JD. Compressive myelopathy presenting as cervical cord neurapraxia: a differential diagnosis of TIA. Neurology 2005; 65:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/10\">",
"      Muraszko KM, Oldfield EH. Vascular malformations of the spinal cord and dura. Neurosurg Clin N Am 1990; 1:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/11\">",
"      Krings T, Geibprasert S. Spinal dural arteriovenous fistulas. AJNR Am J Neuroradiol 2009; 30:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/12\">",
"      Villani F, D'Amico D, Pincherle A, et al. Prolonged focal negative motor seizures: a video-EEG study. Epilepsia 2006; 47:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/13\">",
"      Fisher CM. Transient paralytic attacks of obscure nature: the question of non-convulsive seizure paralysis. Can J Neurol Sci 1978; 5:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/14\">",
"      Fisher CM. Migraine accompaniments versus arteriosclerotic ischemia. Trans Am Neurol Assoc 1968; 93:211.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan, LR. Nonatherosclerotic vasculopathies. In: Caplan's Stroke: A Clinical Approach, 4th ed, Saunders, Philadelphia 2009. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36439/abstract/16\">",
"      Liberman A, Karussis D, Ben-Hur T, et al. Natural course and pathogenesis of transient focal neurologic symptoms during pregnancy. Arch Neurol 2008; 65:218.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1137 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36439=[""].join("\n");
var outline_f35_37_36439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H54661373\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSIENT ISCHEMIC ATTACK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms of TIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSIENT NEUROLOGIC EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Migraine aura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transient global amnesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISTINGUISHING TRANSIENT ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nature of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Progression and course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration and tempo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patient age and gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PERSISTENT NEUROLOGIC DEFICITS WITH ABRUPT ONSET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54661373\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/47/6910\" title=\"table 1\">",
"      TIA symptoms and vascular territories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/25/22940\" title=\"table 2\">",
"      Diff dx transient neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/21/7516\" title=\"table 3\">",
"      Focal transient neuro sx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=related_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38328?source=related_link\">",
"      Transient global amnesia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36440="Doxorubicin: Drug information";
var content_f35_37_36440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxorubicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/52/30533?source=see_link\">",
"    see \"Doxorubicin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/14/20711?source=see_link\">",
"    see \"Doxorubicin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adriamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adriamycin&reg;;",
"     </li>",
"     <li>",
"      Doxorubicin Hydrochloride Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"     <b>",
"      Note:",
"     </b>",
"     Lower dosage should be considered for patients with inadequate marrow reserve (due to old age, prior treatment or neoplastic marrow infiltration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual or typical dosages:",
"     </b>",
"     I.V.: 60-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 21 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 2 weeks (dose dense)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3-4 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2-3 days every 4 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once weekly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F163176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/14/20711?source=see_link\">",
"      see \"Doxorubicin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"     <b>",
"      Note:",
"     </b>",
"     Lower dosage should be considered for patients with inadequate marrow reserve (due to prior treatment or neoplastic marrow infiltration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual/typical dosages:",
"     </b>",
"     Children: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 21 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once weekly",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given as a continuous infusion over 96 hours every 3-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjustments are not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The FDA-approved labeling recommends the following adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 1.2-3 mg/dL: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 3.1-5 mg/dL: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Use is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians: Floyd, 2006:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases 2-3 times ULN: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &gt;3 times ULN or serum bilirubin 1.2-3 mg/dL: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 3.1-5 mg/dL: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;5 mg/dL: Do not administer",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5526740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The following delays and/or dose reductions have been used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neutropenic fever/infection: Consider reducing to 75% of dose in subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Delay treatment until ANC recovers to &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Delay treatment until platelets recover to &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 10 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 10 mg [contains lactose 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 20 mg [contains lactose 100 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 50 mg [contains lactose 250 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 2 mg/mL (5 mL, 10 mL, 25 mL, 75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 2 mg/mL (5 mL, 10 mL, 25 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vesicant. Administer I.V. push over at least 3-5 minutes or by continuous infusion (infusion via central venous line recommended). Avoid extravasation associated with severe ulceration and soft tissue necrosis. Flush with 5-10 mL of I.V. solution before and after drug administration. Incompatible with heparin. Monitor for local erythematous streaking along vein and/or facial flushing (may indicate rapid infusion rate).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, anidulafungin, aztreonam, bleomycin, caspofungin, chlorpromazine, cimetidine, cisplatin, cladribine, cyclophosphamide, dexamethasone sodium phosphate, diphenhydramine, doripenem, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, gemcitabine, hydromorphone, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, metoclopramide, mitomycin, morphine, ondansetron, oxaliplatin, paclitaxel, palonosetron, prochlorperazine edisylate, promethazine, ranitidine, sargramostim, sodium bicarbonate, teniposide, thiotepa, topotecan, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, gallium nitrate, ganciclovir, pemetrexed, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, granisetron, heparin, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cyclophosphamide, droperidol, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, heparin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisplatin, cisplatin and mitomycin, fluorouracil, vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin&rsquo;s disease, malignant lymphoma, soft tissue and bone sarcomas, thyroid cancer, small cell lung cancer, breast cancer, gastric cancer, ovarian cancer, bladder cancer, neuroblastoma, and Wilms' tumor",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9294862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of multiple myeloma, endometrial carcinoma, uterine sarcoma, head and neck cancer, liver cancer, kidney cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOXOrubicin may be confused with DACTINomycin, DAUNOrubicin, DAUNOrubicin liposomal,  doxapram, doxazosin, DOXOrubicin liposomal, epirubicin, IDArubicin, valrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Adriamycin PFS&reg; may be confused with achromycin, Aredia&reg;, Idamycin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Conventional formulation (Adriamycin PFS&reg;, Adriamycin RDF&reg;) may be confused with the liposomal formulation (Doxil&reg;)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use caution when selecting product for preparation and dispensing; indications, dosages and adverse event profiles differ between conventional DOXOrubicin hydrochloride solution and DOXOrubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ADR is an error-prone abbreviation",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxil&reg; may be confused with Doxal&reg; which is a brand name for doxepin in Finland, a brand name for doxycycline in Austria, and a brand name for pyridoxine/thiamine combination in Brazil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rubex, a discontinued brand name for DOXOrubicin in the U.S, is a brand name for ascorbic acid in Ireland",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute cardiotoxicity: Atrioventricular block, bradycardia, bundle branch block,  ECG abnormalities, extrasystoles (atrial or ventricular), sinus tachycardia, ST-T wave changes,  supraventricular tachycardia, tachyarrhythmia, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delayed cardiotoxicity: LVEF decreased, CHF (manifestations include ascites, cardiomegaly, dyspnea, edema, gallop rhythm, hepatomegaly, oliguria, pleural effusion, pulmonary edema, tachycardia); myocarditis, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, photosensitivity, radiation recall, rash; discoloration of saliva, sweat, or tears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, dehydration, infertility (may be temporary), hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, colon necrosis, diarrhea, GI ulceration, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia/neutropenia (75%; nadir: 10-14 days; recovery: by day 21); thrombocytopenia and anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Skin &ldquo;flare&rdquo; at injection site, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, azoospermia, bilirubin increased, coma (when in combination with cisplatin or vincristine), conjunctivitis, fever, gonadal impairment (children), growth failure (prepubertal), hepatitis, hyperpigmentation (nail, skin &amp; oral mucosa), infection, keratitis, lacrimation, myelodysplastic syndrome, neutropenic fever, neutropenic typhlitis, oligospermia, peripheral neurotoxicity (with intra-arterial doxorubicin), phlebosclerosis, radiation recall pneumonitis (children), secondary acute myelogenous leukemia, seizure (when in combination with cisplatin or vincristine), sepsis, shock, Stevens-Johnson syndrome, systemic hypersensitivity (including urticaria, pruritus, angioedema, dysphagia, and dyspnea), toxic epidermal  necrolysis, transaminases increased, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxorubicin, any component of the formulation, or to other anthracyclines or anthracenediones; recent MI, severe myocardial insufficiency, severe arrhythmia; previous therapy with high cumulative doses of doxorubicin, daunorubicin, idarubicin, or other anthracycline and anthracenediones; baseline neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe myelosuppression;",
"     </b>",
"     dose-limiting, primarily leukopenia and neutropenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause cumulative, dose-related, myocardial toxicity (early or delayed).",
"     </b>",
"     Cardiotoxicity is dose-limiting. Total cumulative dose should take into account previous or concomitant treatment with cardiotoxic agents or irradiation of chest. The incidence of irreversible myocardial toxicity increases as the total cumulative (lifetime) dosages approach 450-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur at any dose level. Patients with pre-existing heart disease, hypertension, concurrent administration of other antineoplastic agents, prior or concurrent chest irradiation, advanced age; and infants and children are at increased risk. Alternative administration schedules (weekly or continuous infusions) are associated with less cardiotoxicity. Baseline and periodic monitoring of ECG and LVEF (with either ECHO or MUGA scan) is recommended. Children are at increased for developing delayed cardiotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warnings]: Secondary acute myelogenous leukemia and myelodysplastic syndrome have been reported following treatment.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation/extravasation:",
"     <b>",
"      [U.S. Boxed Warning]: I.V. administration only. Potent vesicant; if extravasation occurs, severe local tissue damage leading to ulceration and necrosis, and pain may occur.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: May cause tumor lysis syndrome and hyperuricemia (in patients with rapidly growing tumors).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in patients with hepatic impairment;",
"     </b>",
"     toxicities may be increased in patients with hepatic impairment; dosage adjustment recommended. Use with caution in patients with hepatobiliary dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children are at increased risk for developing delayed cardiotoxicity; follow-up cardiac function monitoring is recommended. Doxorubicin may contribute to prepubertal growth failure in children; may also contribute to gonadal impairment (usually temporary). Radiation recall pneumonitis has been reported in children receiving concomitant dactinomycin and doxorubicin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation recipients: Use with caution in patients who have received radiation therapy; reduce dosage in patients who are receiving radiation therapy simultaneously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Formulations (conventional vs liposomal): Use caution when selecting product for preparation and dispensing; indications, dosages and adverse event profiles differ between conventional doxorubicin hydrochloride solution and doxorubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Administration of live vaccines to immunosuppressed patients may be hazardous.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of DOXOrubicin. Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of DOXOrubicin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: DOXOrubicin may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May decrease the metabolism of DOXOrubicin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: DOXOrubicin may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease doxorubicin levels). Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenicity and embryotoxicity were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Advise patients to avoid becoming pregnant (females) and to avoid causing pregnancy (males) during treatment. According to the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, doxorubicin, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen, although chemotherapy should not be administered during the first trimester or after 35 weeks gestation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5526739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxorubicin and its metabolites are found in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adriamycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (10 mL): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DOXOrubicin HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (25 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Adriamycin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $66.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (DOXOrubicin HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $66.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count; liver function tests (bilirubin, ALT/AST, alkaline phosphatase); serum uric acid, calcium, potassium, phosphate and creatinine; cardiac function (baseline, periodic, and followup): ECG, left ventricular ejection fraction (echocardiography [ECHO] or multigated radionuclide angiography [MUGA])",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A.D.Mycin (TH);",
"     </li>",
"     <li>",
"      Adriablastina (BG);",
"     </li>",
"     <li>",
"      Adriablastina RD (HR, SG);",
"     </li>",
"     <li>",
"      Adriacin (JP);",
"     </li>",
"     <li>",
"      Adriamycin (AU, CL, DK, FI, GB, NO, SE);",
"     </li>",
"     <li>",
"      Adriamycin CS (SG);",
"     </li>",
"     <li>",
"      Adriamycin PFS (KP);",
"     </li>",
"     <li>",
"      Adriblastin (AT, CH, IL);",
"     </li>",
"     <li>",
"      Adriblastina (AR, BE, CZ, HU, IT, LU, NL, PK, VE);",
"     </li>",
"     <li>",
"      Adriblastina CS (CO);",
"     </li>",
"     <li>",
"      Adriblastina PFS (EE);",
"     </li>",
"     <li>",
"      Adriblastina RD (MX, PL);",
"     </li>",
"     <li>",
"      Adriblastina Soluzione Pronta (IT);",
"     </li>",
"     <li>",
"      Adriblastine (FR);",
"     </li>",
"     <li>",
"      AdriCept (DE);",
"     </li>",
"     <li>",
"      Adricin (ID);",
"     </li>",
"     <li>",
"      Adrim (IN);",
"     </li>",
"     <li>",
"      Adrimedac (DE);",
"     </li>",
"     <li>",
"      Adrosal (PH);",
"     </li>",
"     <li>",
"      Axibin (PH);",
"     </li>",
"     <li>",
"      Caelyx (AR, CH, DE, DK, ES, FR, IT, MX, PT);",
"     </li>",
"     <li>",
"      Colhidrol (AR);",
"     </li>",
"     <li>",
"      Dicladox (AR);",
"     </li>",
"     <li>",
"      DOXO-cell (DE);",
"     </li>",
"     <li>",
"      Doxocris (AR);",
"     </li>",
"     <li>",
"      Doxolem RU (MX);",
"     </li>",
"     <li>",
"      Doxopeg (CO, EC, MX);",
"     </li>",
"     <li>",
"      Doxorbin (AR);",
"     </li>",
"     <li>",
"      Doxorubicin (IN);",
"     </li>",
"     <li>",
"      Doxorubicin Azupharma (DE);",
"     </li>",
"     <li>",
"      Doxorubicin Bigmar (CH);",
"     </li>",
"     <li>",
"      Doxorubicin Bristol (CH);",
"     </li>",
"     <li>",
"      Doxorubicin Ebewe (CH);",
"     </li>",
"     <li>",
"      Doxorubicin Hexal (DE);",
"     </li>",
"     <li>",
"      Doxorubicin Meiji (IN);",
"     </li>",
"     <li>",
"      Doxorubicin NC (DE);",
"     </li>",
"     <li>",
"      Doxorubicin R.P. (DE);",
"     </li>",
"     <li>",
"      Doxorubicin &rdquo;Paranova&rdquo; (DK);",
"     </li>",
"     <li>",
"      Doxorubicina (ES);",
"     </li>",
"     <li>",
"      Doxorubicina Asofarma (AR);",
"     </li>",
"     <li>",
"      Doxorubicina Delta Farma (AR);",
"     </li>",
"     <li>",
"      Doxorubicina Faulding (AR);",
"     </li>",
"     <li>",
"      Doxorubicina Filaxis (AR);",
"     </li>",
"     <li>",
"      Doxorubicina Gador (AR);",
"     </li>",
"     <li>",
"      Doxorubicine Asta (FR);",
"     </li>",
"     <li>",
"      Doxorubicine Dakota (FR);",
"     </li>",
"     <li>",
"      Doxorubin (CH, DK, NL);",
"     </li>",
"     <li>",
"      Doxosol (FI);",
"     </li>",
"     <li>",
"      Doxotec (MX);",
"     </li>",
"     <li>",
"      Doxtie (EC, MX);",
"     </li>",
"     <li>",
"      Ebedoxo (SG);",
"     </li>",
"     <li>",
"      Farmiblastina (ES);",
"     </li>",
"     <li>",
"      Flavicina (AR);",
"     </li>",
"     <li>",
"      Leubex (AR);",
"     </li>",
"     <li>",
"      Nagun (AR);",
"     </li>",
"     <li>",
"      Oncodox (PE);",
"     </li>",
"     <li>",
"      Pallagicin (HU);",
"     </li>",
"     <li>",
"      Quimotus (AR);",
"     </li>",
"     <li>",
"      Rastocin (HR);",
"     </li>",
"     <li>",
"      Ribodoxo (DE);",
"     </li>",
"     <li>",
"      Roxorin (PY, UY);",
"     </li>",
"     <li>",
"      Rubex (BR);",
"     </li>",
"     <li>",
"      Sindroxocin (HK, PH);",
"     </li>",
"     <li>",
"      Urokit Doxo-cell (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor (&lt;50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 809-1214 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; to many body tissues, particularly liver, spleen, kidney, lung, heart; does not distribute into the CNS; crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 70% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic to doxorubicinol (active), then to inactive aglycones, conjugated sulfates, and glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: Doxorubicin: 1-3 hours; Metabolites: 3-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 17-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Male: 54 hours; Female: 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~40% to 50% as unchanged drug); urine (~5% to 12% as unchanged drug and metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Male: 113 L/hour; Female: 44 L/hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown JR and Iman SH, &ldquo;Recent Studies on Doxorubicin and Its Analogues,&rdquo;",
"      <i>",
"       Prog Med Chem",
"      </i>",
"      , 1984, 21:169-236.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/6400135/pubmed\" id=\"6400135\" target=\"_blank\">",
"        6400135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummings J and Smyth JF, &ldquo;Pharmacology of Adriamycin: The Message to the Clinician,&rdquo;",
"      <i>",
"       Eur J Cancer Clin Oncol",
"      </i>",
"      , 1988, 24(4):579-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/3289943/pubmed\" id=\"3289943\" target=\"_blank\">",
"        3289943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curran CF, &ldquo;Acute Doxorubicin Overdoses,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 115(11):913-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curran CF and Luce JK, &ldquo;Accidental Acute Exposure to Doxorubicin,&rdquo;",
"      <i>",
"       Cancer Nurs",
"      </i>",
"      , 1989, 12(6):329-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/2590899/pubmed\" id=\"2590899\" target=\"_blank\">",
"        2590899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis HL and Davis TE, &ldquo;Daunorubicin and Adriamycin in Cancer Treatment: An Analysis of Their Roles and Limitations,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1979, 63(5):809-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/378369/pubmed\" id=\"378369\" target=\"_blank\">",
"        378369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon KB, Tajuddin A, Guitart J, et al, &ldquo;Hand-Foot Syndrome Associated With Liposome-Encapsulated Doxorubicin Therapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1995, 75(8):2169-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/7697608/pubmed\" id=\"7697608\" target=\"_blank\">",
"        7697608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ishii E, Hara T, Ohkubo K, et al, &ldquo;Treatment of Childhood Acute Lymphoblastic Leukemia With Intermediate Dose Cytosine Arabinoside and Adriamycin,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1986, 14(2):73-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/3458999/pubmed\" id=\"3458999\" target=\"_blank\">",
"        3458999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauvin R, Miglianico L, and Hellegouarc'h R, &ldquo;Skin Cancer Occurring 10 Years After the Extravasation of Doxorubicin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(11):754.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, Benjamin RS, Mackay B, et al, &ldquo;Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1982, 96(2):133-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/7059060/pubmed\" id=\"7059060\" target=\"_blank\">",
"        7059060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Namer M, &ldquo;Anthracyclines in the Adjuvant Treatment of Breast Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 45(Suppl 2):4-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/7693421/pubmed\" id=\"7693421\" target=\"_blank\">",
"        7693421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 2.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert CF, Nesser ME, and Thompson DF, &ldquo;Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(9):1063-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/7803884/pubmed\" id=\"7803884\" target=\"_blank\">",
"        7803884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speth PA, van Hoesel QG, and Haanen C, &ldquo;Clinical Pharmacokinetics of Doxorubicin,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 15(1):15-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/3042244/pubmed\" id=\"3042244\" target=\"_blank\">",
"        3042244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speyer JL, Green MD, Kramer E, et al, &ldquo;Protective Effect of the Bispiperazinedione ICRF-187 Against Doxorubicin-Induced Cardiac Toxicity in Women With Advanced Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 319(12):745-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/3137469/pubmed\" id=\"3137469\" target=\"_blank\">",
"        3137469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmerman S, Adkins D, Graham M, et al, &ldquo;Irreversible, Severe, Congestive Cardiomyopathy Occurring in Association With Interferon Alpha Therapy,&rdquo;",
"      <i>",
"       Cancer Biother",
"      </i>",
"      , 1994, 9(4):291-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/37/36440/abstract-text/7719376/pubmed\" id=\"7719376\" target=\"_blank\">",
"        7719376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9391 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36440=[""].join("\n");
var outline_f35_37_36440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708686\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163149\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163150\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163199\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163154\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163176\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163155\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163156\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163157\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526740\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163127\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163112\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163130\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163205\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163128\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9294862\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163208\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163197\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163133\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163116\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163121\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163145\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163123\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163135\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163163\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526739\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323122\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163125\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163136\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163115\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163132\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/52/30533?source=related_link\">",
"      Doxorubicin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/14/20711?source=related_link\">",
"      Doxorubicin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36441="Causes of congenital and acquired sideroblastic anemias";
var content_f35_37_36441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of congenital and acquired sideroblastic anemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Sylvia S Bottomley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/37/36441/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/37/36441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a number of forms of congenital sideroblastic anemia, underlying defects have been established at the molecular level (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ); they primarily disrupt cellular pathways in the mitochondria of erythroid cells (",
"    <a class=\"graphic graphic_figure graphicRef86551 \" href=\"mobipreview.htm?23/56/24455\">",
"     figure 1",
"    </a>",
"    ). These defects involve genes encoding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The erythroid 5-aminolevulinate synthase isoform (ALAS2)",
"     </li>",
"     <li>",
"      A mitochondrial amino acid transporter (SLC25A38)",
"     </li>",
"     <li>",
"      Glutaredoxin 5 (GLRX5)",
"     </li>",
"     <li>",
"      Ferrochelatase (FECH)",
"     </li>",
"     <li>",
"      A putative mitochondrial (sulfur compound) exporter (ABCB7)",
"     </li>",
"     <li>",
"      Pseudouridine synthase 1 (PUS1); tyrosyl-tRNA synthetase (YARS2)",
"     </li>",
"     <li>",
"      Multiple mitochondrial proteins (Pearson syndrome).",
"     </li>",
"     <li>",
"      The thiamine transporter-1 (SLC19A2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in many patients with congenital as well as acquired clonal forms of sideroblastic anemia, the pathogenetic defect remains to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. In the metabolic sideroblastic anemias, the role of the causative factors is only partly understood (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ). Regardless of cause, the defining characteristic of these disorders, the pathologic accumulation of mitochondrial iron in erythroblasts, results from:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient production of protoporphyrin to utilize the iron that is delivered to erythroblasts,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Faults in mitochondrial functions that affect iron pathways or impair mitochondrial protein synthesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current understanding of congenital and acquired defects of heme synthesis and of mitochondrial function leading to the sideroblastic anemias will be presented here. The pathophysiology, clinical aspects, diagnosis, and treatment of the sideroblastic anemias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35750?source=see_link\">",
"     \"Pathophysiology of the sideroblastic anemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONGENITAL SIDEROBLASTIC ANEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders are genetically and clinically heterogeneous, with diverse underlying causes, inheritance patterns, clinical phenotypes, and associated features (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ). The majority appear as isolated anemia. Much less common are syndromic forms affecting multiple systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     X-linked sideroblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linkage of X-linked sideroblastic anemia (XLSA) to the ALAS2 locus was established in several kindreds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ]. Heterogeneous mutations in the catalytic domain of ALAS2, and, in three families, mutations in the promoter region of the gene, are associated with the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]. To date, a wide spectrum of mutations has been identified in at least 100 unrelated kindreds or probands; among 65 distinct mutations (",
"    <a class=\"graphic graphic_figure graphicRef80888 \" href=\"mobipreview.htm?6/30/6639\">",
"     figure 2",
"    </a>",
"    ) only 22 percent have occurred in more than one unrelated case or family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly one-third of the probands identified are women, who express the disorder because of highly skewed inactivation of their X chromosomes in hematopoietic tissue, favoring expression of the mutant allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ]. As the hematologic phenotype in most of these cases is indistinguishable from that of acquired clonal sideroblastic anemia (ie, refractory anemia with ring sideroblasts), analysis of the X chromosome inactivation pattern as well as the ALAS2 gene for mutations has important diagnostic and prognostic value in women presenting with sideroblastic anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     5-Aminolevulinate synthase",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-aminolevulinate synthase (ALAS, previously called delta-aminolevulinic acid synthase), is the first and rate-limiting enzyme of the heme synthetic pathway. It requires pyridoxal 5&rsquo;-phosphate (PLP), the active form of pyridoxine (Vitamin B",
"    <sub>",
"     6",
"    </sub>",
"    ), as an obligatory cofactor (",
"    <a class=\"graphic graphic_figure graphicRef66466 \" href=\"mobipreview.htm?6/39/6773\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link&amp;anchor=H4#H4\">",
"     \"Porphyrias: An overview\", section on 'Regulation of heme synthesis'",
"    </a>",
"    .) There are two isoforms of the enzyme:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The housekeeping form (ALAS1), encoded by a gene on chromosome 3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], which is expressed ubiquitously in all body cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The erythroid-specific form (ALAS2), encoded by a gene on the X chromosome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]. It is expressed only in erythroid cells upon their differentiation, in concert with other erythroid genes, through the action of erythropoietin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ALAS2 enzyme is essential for erythroid cell development. In a knock-out mouse model, ALAS2-null embryos succumb within two weeks of development; animals chimeric for the ALAS2 deficiency exhibit typical ring sideroblasts with mitochondrial siderosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations affecting ALAS1 activity have not been described and are likely incompatible with life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Functional effects of mutant ALAS2 enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of the normal ALAS2 enzyme and its mutants must be viewed in full perspective, which includes the subcellular pathway that the enzyme takes from its generation on cytosolic ribosomes to its translocated site of action in the mitochondrial matrix, as well as factors that regulate ALAS2 expression and activity.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recombinant expression studies indicate that many but not all of the ALAS2 mutant enzymes identified in patients have reduced enzymatic activity, with altered kinetics or stability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/6,18-20\">",
"       6,18-20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Some mutant enzymes have no enzymatic activity. Thus far, these have been encountered only in females expressing the disease, consistent with retained functional enzyme only from their residual active normal allele [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/11,18\">",
"       11,18",
"      </a>",
"      ]. Apparent absence of affected males in their families implies that such ALAS2 defects are lethal in hemizygous males.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Some ALAS2 mutants with normal in vitro activity lack the ability to associate with or bind to the enzyme succinyl CoA synthetase, presumably a prerequisite for availability of the substrate succinyl CoA in vivo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Promoter mutations in the ALAS2 gene cause reduced transcription of the mRNA for the enzyme [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/6,22\">",
"       6,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Molecular basis for pyridoxine responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A three-dimensional structure model of the human ALAS2 enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/23\">",
"     23",
"    </a>",
"    ] and the crystal structure of the significantly homologous ALAS of R. capsulatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/24\">",
"     24",
"    </a>",
"    ] allow predictions of altered enzyme activity or pyridoxine responsiveness for the naturally occurring ALAS2 mutations that give rise to XLSA. For example, mutations changing an amino acid critical for substrate binding, stability, or folding of the enzyme are usually refractory to treatment with pyridoxine supplements, whereas mutations altering an amino acid located in the vicinity of the pyridoxal 5'-phosphate (PLP) binding site exhibit a response to pyridoxine. Two cases illustrate this phenomenon in vivo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a male patient with XLSA, the expressed activity of the abnormal ALAS2 enzyme, which carried a mutation in exon 5 within the catalytic domain (",
"      <a class=\"graphic graphic_figure graphicRef80888 \" href=\"mobipreview.htm?6/30/6639\">",
"       figure 2",
"      </a>",
"      ), was 15 percent of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/25\">",
"       25",
"      </a>",
"      ]. This activity was increased up to 34 percent by the addition of PLP, consistent with his clinical response to treatment with pyridoxine.",
"     </li>",
"     <li>",
"      In a patient with a mutation in exon 8 very near the PLP binding site of the enzyme (",
"      <a class=\"graphic graphic_figure graphicRef80888 \" href=\"mobipreview.htm?6/30/6639\">",
"       figure 2",
"      </a>",
"      ), the low ALAS activity in vivo observed during relapse off pyridoxine was restored to normal after re-administration of pyridoxine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mitochondrial transporter SLC25A38 defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autosomal recessive sideroblastic anemia is caused by mutations in the erythroid specific mitochondrial amino acid transporter SLC25A38 (",
"    <a class=\"graphic graphic_figure graphicRef86551 \" href=\"mobipreview.htm?23/56/24455\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/2\">",
"     2",
"    </a>",
"    ]. This transporter likely facilitates ALA production by importing glycine into mitochondria, or possibly by exchanging glycine for ALA across the mitochondrial inner membrane, in order to support the high level of heme synthesis in erythroid cells.",
"   </p>",
"   <p>",
"    Multiple biallelic mutations in the SLC25A38 gene associated with congenital sideroblastic anemia have been identified in at least 26 probands or families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. This form is relatively common among the congenital sideroblastic anemias, second only to XLSA in occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glutaredoxin 5 (GLRX5) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitochondrial enzyme GLRX5 is required for the synthesis of iron-sulfur clusters (Fe-S), prosthetic groups that are essential components of various mitochondrial and cytosolic proteins, including iron regulatory protein 1 (IRP1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/28\">",
"     28",
"    </a>",
"    ]. In a zebrafish mutant (shiraz) deficient in GLRX5, IRP1 cannot acquire the Fe-S and thus inhibits ALAS2 translation, causing severe hypochromic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A homozygous mutation in the GLRX5 gene associated with sideroblastic anemia has been described in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/30\">",
"     30",
"    </a>",
"    ]. The mutation affects intron 1 splicing and markedly reduces production of normal GLRX5 mRNA, leading to impaired heme biosynthesis and disrupted cellular iron homeostasis in erythroid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Erythropoietic protoporphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of ferrochelatase (",
"    <a class=\"graphic graphic_figure graphicRef66466 \" href=\"mobipreview.htm?6/39/6773\">",
"     figure 3",
"    </a>",
"    ), due to numerous identified mutations, underlies the porphyric disorder erythropoietic protoporphyria (EPP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/31\">",
"     31",
"    </a>",
"    ]. Mild microcytic anemia occurs in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of ring sideroblasts was found in 10 patients with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] but not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/35\">",
"     35",
"    </a>",
"    ]. However, a systematic study of this abnormality in EPP has not been performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15834?source=see_link\">",
"     \"Erythropoietic protoporphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The low enzymatic activity of ferrochelatase in EPP leads to little compromise of erythroid heme synthesis, consistent with the observed accumulation of excess free protoporphyrin only during the final stages of erythroid maturation, when the residual ferrochelatase activity becomes rate limiting for heme production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, iron assimilation appears to be restricted to match the ferrochelatase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Congenital sideroblastic anemia without identified molecular defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in the known genes causing congenital sideroblastic anemia are not found in at least 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Families with affected siblings of both genders, suggesting autosomal inheritance",
"     </li>",
"     <li>",
"      Individuals with the sporadic congenital form",
"     </li>",
"     <li>",
"      One family with mild anemia in which a pedigree study suggested maternal inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some instances, associated features suggested an undefined syndromic form(s). The causative defects are actively being sought in research laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sideroblastic anemia as a component of genetic syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     X-linked sideroblastic anemia with ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked sideroblastic anemia with ataxia",
"    <span class=\"nowrap\">",
"     (XLSA/A)",
"    </span>",
"    is a rare and unique phenotype of congenital sideroblastic anemia, characterized by relatively mild anemia, increased erythrocyte protoporphyrins, unresponsiveness to pyridoxine, and non-progressive spinocerebellar ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/37\">",
"     37",
"    </a>",
"    ]. It has been linked to the phosphoglycerate kinase locus at Xq13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/38\">",
"     38",
"    </a>",
"    ] and not to the ALAS2 locus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/39\">",
"     39",
"    </a>",
"    ]. The molecular defect resides in the ABCB7 transporter gene; a missense mutation leading to substitution of a conserved amino acid was first found in a previously described large kindred with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/40\">",
"     40",
"    </a>",
"    ]. Three additional mutations of ABCB7 were subsequently reported in three further families with",
"    <span class=\"nowrap\">",
"     XLSA/A",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ABCB7 protein, an ATP-binding cassette transporter, is essential for hematopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/44\">",
"     44",
"    </a>",
"    ] and is involved in the generation of Fe-S for cytosolic iron-sulfur cluster-containing proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. The link between the molecular defect and the phenotype of",
"    <span class=\"nowrap\">",
"     XLSA/A",
"    </span>",
"    remains to be defined; in erythroid cells heme synthesis is likely affected indirectly as in glutaredoxin 5 deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Myopathy, lactic acidosis, and sideroblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common features of myopathy, lactic acidosis and sideroblastic anemia (MLASA), define a rare autosomal recessive oxidative phosphorylation disorder, with progressive exercise intolerance during childhood, onset of sideroblastic anemia usually around adolescence, basal lactic academia, and mitochondrial myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/46\">",
"     46",
"    </a>",
"    ]. Underlying defects reside in the gene encoding pseudouridine synthase 1 (PUS1). Missense mutations in three families of Jewish Iranian descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/47,48\">",
"     47,48",
"    </a>",
"    ] and distinct nonsense mutations in an Italian family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/49\">",
"     49",
"    </a>",
"    ] and in a Yemini child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/5\">",
"     5",
"    </a>",
"    ] have so far been identified, predicting inactive protein. Further studies demonstrated that the defects are associated with loss of tRNA pseudouridylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=see_link&amp;anchor=H7#H7\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'Predominantly multisystem disease with myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two pathogenic mutations in another gene, encoding mitochondrial tyrosyl-tRNA synthetase (YARS2), are also associated with this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/3\">",
"     3",
"    </a>",
"    ]. In two unrelated families of Lebanese background with the first reported mutation, onset of severe anemia was in infancy or childhood. The myopathy is more marked than that reported for PUS1 mutation positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/3\">",
"     3",
"    </a>",
"    ]. In a separate case the anemia was detected in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/51\">",
"     51",
"    </a>",
"    ]. The missense mutations reduce levels of the enzyme, leading to decreased mitochondrial protein synthesis and respiratory chain dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/3,51\">",
"     3,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How these mitochondrial protein deficiencies lead to mitochondrial iron accumulation and anemia has not been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1551515\">",
"    <span class=\"h3\">",
"     Pearson marrow-pancreas syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal features of this congenital multisystem mitochondrial disorder are severe hypoplastic anemia, ring sideroblasts in the bone marrow, neutropenia, thrombocytopenia, pancreatic insufficiency, lactic acidosis, and failure to thrive from infancy or early childhood, although clinical variants occur. Because of atypical presentations of the disease in the neonatal period, its clinical onset is said to be often overlooked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=see_link&amp;anchor=H15#H15\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'Pearson syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The syndrome is caused by sporadic large deletions or rearrangements of mitochondrial DNA, resulting in the loss of multiple proteins encoded by the mitochondrial genome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/53\">",
"     53",
"    </a>",
"    ]. Approximately one-half of cases are heteroplasmic for a 4977 bp deletion that involves mitochondrially encoded subunits of several respiratory complexes. These major molecular defects are associated with pronounced abnormalities in the ultrastructure of erythroblast mitochondria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/54\">",
"     54",
"    </a>",
"    ]. Respiratory enzyme defects that may affect mitochondrial iron pathways are postulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Thiamine-responsive megaloblastic anemia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome, also known as Rogers syndrome, is recessively inherited and its cardinal features are megaloblastic anemia, diabetes mellitus, and sensorineural deafness manifesting between infancy and adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/55\">",
"     55",
"    </a>",
"    ]. Hematologic findings include the ring sideroblastic abnormality and variable degrees of neutropenia and thrombocytopenia.",
"   </p>",
"   <p>",
"    The underlying defect resides in the SLC19A2 gene, which encodes a high-affinity thiamine transporter protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Heterogeneous mutations have been described in many families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/59\">",
"     59",
"    </a>",
"    ]. Most are null mutations; some mutant proteins are not properly targeted to the cell membrane for their site of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The megaloblastosis is due to defective nucleic acid synthesis because limited intracellular thiamine affects the pentose phosphate pathway and production of ribose-5-P [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/62\">",
"     62",
"    </a>",
"    ]. The ring sideroblast feature may relate to the role of thiamine in the generation of succinyl coenzyme A, a substrate of ALAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thiamine (vitamin B1) in pharmacologic doses usually improves the anemia and the diabetes initially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/55\">",
"     55",
"    </a>",
"    ], but becomes ineffective in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACQUIRED CLONAL SIDEROBLASTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder arises in conjunction with the clonal overgrowth of a genetically altered hematopoietic progenitor cell that has a proliferative advantage over normal precursor cells. Thus, it is included as a subtype(s) of the myelodysplastic syndromes (MDS), where it is designated as refractory anemia with ringed sideroblasts (RARS).",
"   </p>",
"   <p>",
"    A variant of RARS associated with thrombocytosis (RARS-T) frequently carries the JAK2 V617F mutation, which appears to drive the clonal proliferation as in myeloproliferative syndromes (hence also called",
"    <span class=\"nowrap\">",
"     \"myelodysplastic/myeloproliferative",
"    </span>",
"    syndrome, unclassifiable\" by the WHO) but is not related to the sideroblastic phenotype. In a third MDS subtype in which the other cell lineages are affected (RCMD-RS), the clone also carries a defect causing the ring sideroblast abnormality (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While defective erythropoiesis in this disorder has features of impaired hemoglobin synthesis, as reflected in the presence of a hypochromic erythrocyte population in the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/65\">",
"     65",
"    </a>",
"    ], no consistent defects in protoporphyrin synthesis in marrow cells have been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ]. A somatic ALAS2 mutation was identified in only one case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/66\">",
"     66",
"    </a>",
"    ]. However, a common feature is mild to moderate elevation of free erythrocyte protoporphyrin, and impaired marrow ferrochelatase (",
"    <a class=\"graphic graphic_figure graphicRef66466 \" href=\"mobipreview.htm?6/39/6773\">",
"     figure 3",
"    </a>",
"    ) activity was observed in approximately one-half of patients studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ]. Very uncommonly clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical features resemble erythropoietic protoporphyria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1,67\">",
"     1,67",
"    </a>",
"    ], which may now be explained by a likely acquired deletion of a ferrochelatase allele due to a cytogenetic abnormality of the clonal disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/68\">",
"     68",
"    </a>",
"    ]. One study found the transcript for ABCB7 to be reduced in RARS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/69\">",
"     69",
"    </a>",
"    ], suggesting defective iron-sulfur cluster generation. However, it is not known whether expression of the ABCB7 protein is altered, or whether the finding represents a secondary effect.",
"   </p>",
"   <p>",
"    Intraclonal heterogeneity of the erythroblast phenotype (ie, a variable amount of mitochondrial iron overload evident from cell to cell), had suggested a heteroplasmic state due to a mitochondrial defect. Extensive analysis of mitochondrial DNA in patients with RARS as well as other myelodysplastic syndromes has revealed a wide spectrum of heteroplasmic mutations in approximately one-half of cases that occur across the mitochondrial genome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/70\">",
"     70",
"    </a>",
"    ]. While their functional importance overall remains unclear, some mutations may affect mitochondrial iron metabolism (eg, if they affect cytochrome oxidase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/71\">",
"     71",
"    </a>",
"    ]. In line with the natural history of the disorder, the type of mutation may determine the degree of increased apoptosis, involvement of other cell lineages, as well as associated genetic instability of progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/72\">",
"     72",
"    </a>",
"    ], which might serve to promote occasional leukemic transformation.",
"   </p>",
"   <p>",
"    Genome and exome sequencing studies have revealed that components of the &ldquo;spliceosome&rdquo;, which is responsible for the maturation of primary mRNA transcripts into mature mRNAs lacking introns, are commonly mutated in all forms of MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Particularly prevalent were heterozygous missense mutations in SF3B1 (splicing factor 3B, subunit 1) in patients with RARS (82.3 percent of cases) and RCMD-RS (76 percent); they were present only infrequently in cases of MDS without ring sideroblasts (6.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/73-77\">",
"     73-77",
"    </a>",
"    ]. The link between these novel observations and mitochondrial iron metabolism or the ring sideroblast abnormality is under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256819286#H256819286\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ACQUIRED METABOLIC SIDEROBLASTIC ANEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroid heme biosynthesis or mitochondrial functions may be adversely affected by diverse acquired factors (eg, ethanol, drugs, copper deficiency, and hypothermia), leading to a sideroblastic anemia that is fully reversible when the offending factor is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ring sideroblast abnormality is one of many components contributing to the anemia associated with alcoholism. It is encountered in 25 to 30 percent of anemic alcoholic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], and most characteristically in the presence of malnutrition and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=see_link\">",
"     \"Alcohol abuse and hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disruption of heme synthesis in such patients appears to be multifactorial, including inhibition of several enzymatic steps in the heme pathway, such as 5-aminolevulinate dehydratase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, and ferrochelatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef66466 \" href=\"mobipreview.htm?6/39/6773\">",
"     figure 3",
"    </a>",
"    ). However, the activities of ALAS and porphobilinogen deaminase are increased, perhaps through a feedback mechanism.",
"   </p>",
"   <p>",
"    Inconsistent abnormalities observed in several past studies do not provide a uniform target site for alcohol or its metabolites adversely affecting vitamin B6 metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ]. Of interest, ethanol and acetaldehyde preferentially suppress erythroid colony formation more than myeloid colony formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/82\">",
"     82",
"    </a>",
"    ]. This effect is partially reversed by folinic acid and pyridoxine. Direct effects of ethanol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acetaldehyde on mitochondrial protein synthesis, as observed in the hepatocyte [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/83\">",
"     83",
"    </a>",
"    ], may also be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prototypical drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ) produce the sideroblastic anemia phenotype. The incidence of anemia following the use of these agents is variable, depending on dose and duration of drug intake. The presence of an occult marrow defect has also been implicated for manifestation of the drug effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Isoniazid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    (INH) interferes with vitamin B6 metabolism by reacting with pyridoxal to form a hydrazone, and through inhibition of pyridoxal phosphokinase, depriving ALAS of its product, pyridoxal 5'-phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/84\">",
"     84",
"    </a>",
"    ]. The anti-tuberculosis agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    also have anti-vitamin B6",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-ALAS properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chloramphenicol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    causes the ring sideroblast abnormality in a dose-dependent manner, and also suppresses erythropoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/84\">",
"     84",
"    </a>",
"    ]. These effects are mediated through inhibition of mitochondrial protein synthesis at the level of mRNA translation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/84,86\">",
"     84,86",
"    </a>",
"    ]. As with alcohol, erythroid colony growth is more sensitive to inhibition by chloramphenicol than is granulocyte colony growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1551200\">",
"    <span class=\"h3\">",
"     Linezolid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    , a more recently used antibiotic, produces the ring sideroblast abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/88\">",
"     88",
"    </a>",
"    ]. Its toxicity resembles that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    in that it also inhibits mitochondrial protein synthesis by blocking assembly of the initiation complex, while chloramphenicol inhibits peptide elongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Copper deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deficiency is an uncommon occurrence in man, due to the low daily requirements of the metal relative to its content in food. However, nutritional copper deficiency is encountered in several clinical settings and typically leads to a sideroblastic anemia and neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Copper deficiency disrupts iron metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ] and affects stem cell differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal absorption and mobilization of iron from reticuloendothelial cells and hepatocytes to transferrin are impaired because of the associated lack of ceruloplasmin and its ferroxidase function in these steps.",
"     </li>",
"     <li>",
"      Heme synthesis from ferric iron and protoporphyrin is decreased, presumably because the reduction of ferric iron to ferrous iron is defective secondary to the diminished activity of the copper-containing enzyme cytochrome oxidase.",
"     </li>",
"     <li>",
"      CD34 positive cell differentiation and stem cell renewal are impaired, perhaps also responsible for the neutropenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Zinc toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of excess zinc induces an increase in the intestinal protein metallothionein. This protein preferentially binds copper, displacing zinc from metallothionein, prevents its absorption and enhances its excretion, leading to clinical copper deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neurologic and hematologic syndrome associated with copper deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combined system disorder of sideroblastic anemia, neutropenia, and various neurologic manifestations (eg, myelopathy, peripheral neuropathy) from profound copper deficiency has been recognized over the past decade. Apart from the nutritional factors and zinc excess, the copper transport protein Ctr1, essential for intestinal copper absorption, may be a candidate site for derangements in acquired copper deficiency in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/91\">",
"     91",
"    </a>",
"    ]. The role of copper homeostasis in several genetic disorders provides a background for the central nervous system manifestations of this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sideroblastic abnormality has been described in three patients during episodic hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/93\">",
"     93",
"    </a>",
"    ]. This clinical observation reflects the known sensitivity of several mitochondrial functions (eg, translocation of proteins into mitochondria, heme synthesis, and iron incorporation into hemoglobin) to reduced temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DISORDERS OF ERYTHROID HEME SYNTHESIS WITHOUT RING SIDEROBLASTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Lead poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of authentic ring sideroblasts in lead poisoning is not well documented, although lead poisoning is frequently listed as a cause of sideroblastic anemia. Specifically, this author and colleagues were unable to detect ring sideroblasts in the bone marrows of 12 patients with established lead intoxication and variably severe anemia.",
"   </p>",
"   <p>",
"    The anemia of lead poisoning results, in part, from inhibitory effects of lead on heme biosynthesis. Lead inhibits most of the enzymes in the heme pathway to varying degrees, ALA dehydratase being the most sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/37/36441/abstract/1,84\">",
"     1,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5656?source=see_link&amp;anchor=H4#H4\">",
"     \"ALA dehydratase porphyria\", section on 'Inhibition of enzymatic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In erythroid cells, lead also limits iron delivery to ferrochelatase. As a result, as in iron deficiency, the surrogate metal zinc is inserted into protoporphyrin and accumulates in excess amounts in red cells, where it is detected as erythrocyte zinc protoporphyrin. Reduced delivery of iron to the site of heme formation likely accounts for the usual absence of the ring sideroblast abnormality in lead intoxication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15834?source=see_link\">",
"     \"Erythropoietic protoporphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11025473\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of cause, accumulation of mitochondrial iron in erythroblasts (ie, ring sideroblast formation) results from insufficient production of protoporphyrin, or faults in mitochondrial functions that disrupt cellular iron metabolism or impair mitochondrial protein synthesis (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef86551 \" href=\"mobipreview.htm?23/56/24455\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Congenital sideroblastic anemias",
"      </strong>",
"      &mdash; These disorders are genetically and clinically heterogeneous with diverse underlying causes, inheritance patterns, clinical phenotypes, and associated features. Most appear as isolated anemia while uncommonly the defect also affects other systems (ie, syndromic sideroblastic anemias). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Congenital sideroblastic anemias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Acquired clonal sideroblastic anemia",
"      </strong>",
"      &mdash; This disorder is included as a subtype(s) of the myelodysplastic syndromes (MDS), where it is designated as refractory anemia with ringed sideroblasts (RARS). It also occurs as two variants when associated with thrombocytosis (RARS-T) or with other cytopenias (RCMD-RS). The fundamental cause of these syndromes is undefined. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acquired clonal sideroblastic anemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H359898#H359898\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Refractory anemia with ring sideroblasts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acquired metabolic sideroblastic anemia",
"      </strong>",
"      &mdash; Diverse factors that include alcohol, certain drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      ), copper deficiency (zinc toxicity), and hypothermia can lead to a sideroblastic anemia. This condition is fully reversible when the offending factor is removed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acquired metabolic sideroblastic anemias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bottomley SS. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 12th ed, Greer JP, Foerster J, Rodgers GM, et al. (Eds), Lippincott, Williams and Wilkins, Philadelphia 2008. p.835.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/2\">",
"      Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009; 41:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/3\">",
"      Riley LG, Cooper S, Hickey P, et al. Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome. Am J Hum Genet 2010; 87:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/4\">",
"      Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol 2008; 143:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/5\">",
"      Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/6\">",
"      Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/7\">",
"      May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia. Haematologica 1998; 83:56.",
"     </a>",
"    </li>",
"    <li>",
"     The Human Gene Mutation Database; HGMD&reg;Professional 2012.2 file://www.hgmd.org (Accessed on September 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/9\">",
"      Bottomley SS, Wise PD, Wasson EG, et al. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet 1998; 63(Suppl):A352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/10\">",
"      Cazzola M, May A, Bergamaschi G, et al. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 2000; 96:4363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/11\">",
"      Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 2006; 37:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/12\">",
"      Sutherland GR, Baker E, Callen DF, et al. 5-Aminolevulinate synthase is at 3p21 and thus not the primary defect in X-linked sideroblastic anemia. Am J Hum Genet 1988; 43:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/13\">",
"      Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 1990; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/14\">",
"      May BK, Dogra SC, Sadlon TJ, et al. Molecular regulation of heme biosynthesis in higher vertebrates. Prog Nucleic Acid Res Mol Biol 1995; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/15\">",
"      Cox TC, Bawden MJ, Abraham NG, et al. Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am J Hum Genet 1990; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/16\">",
"      Nakajima O, Takahashi S, Harigae H, et al. Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload. EMBO J 1999; 18:6282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/17\">",
"      Nakajima O, Okano S, Harada H, et al. Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells 2006; 11:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/18\">",
"      Bottomley SS, Wise PD, Wasson EG, et al. The spectrum of molecular defects in the erythroid 5-aminolevulinate synthase gene in hereditary sideroblastic anemia (abstract). Blood 1998; 92:669a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/19\">",
"      Furuyama K, Harigae H, Heller T, et al. Arg452 substitution of the erythroid-specific 5-aminolaevulinate synthase, a hot spot mutation in X-linked sideroblastic anaemia, does not itself affect enzyme activity. Eur J Haematol 2006; 76:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/20\">",
"      Bishop DF, Tchaikovskii V, Hoffbrand AV, et al. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the &beta;-subunit of succinyl-CoA synthetase (SUCLA2). J Biol Chem 2012; 287:28943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/21\">",
"      Furuyama K, Sassa S. Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest 2000; 105:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/22\">",
"      Bekri S, May A, Cotter PD, et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 2003; 102:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/23\">",
"      Shoolingin-Jordan PM, Al-Daihan S, Alexeev D, et al. 5-Aminolevulinic acid synthase: mechanism, mutations and medicine. Biochim Biophys Acta 2003; 1647:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/24\">",
"      Astner I, Schulze JO, van den Heuvel J, et al. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J 2005; 24:3166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/25\">",
"      Harigae H, Furuyama K, Kudo K, et al. A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia. Am J Hematol 1999; 62:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/26\">",
"      Cox TC, Bottomley SS, Wiley JS, et al. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/27\">",
"      Kannengiesser C, Sanchez M, Sweeney M, et al. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica 2011; 96:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/28\">",
"      Ye H, Jeong SY, Ghosh MC, et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 2010; 120:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/29\">",
"      Wingert RA, Galloway JL, Barut B, et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 2005; 436:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/30\">",
"      Camaschella C, Campanella A, De Falco L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/31\">",
"      R&uuml;fenacht UB, Gouya L, Schneider-Yin X, et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 1998; 62:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/32\">",
"      Holme SA, Worwood M, Anstey AV, et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007; 110:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/33\">",
"      Scott AJ, Ansford AJ, Webster BH, Stringer HC. Erythropoietic protoporphyria with features of a sideroblastic anaemia terminating in liver failure. Am J Med 1973; 54:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/34\">",
"      Rademakers LH, Koningsberger JC, Sorber CW, et al. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 1993; 23:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/35\">",
"      Bottomley SS, Tanaka M, Everett MA. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med 1975; 86:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/36\">",
"      Tuckfield A, Ratnaike S, Hussein S, Metz J. A novel form of hereditary sideroblastic anaemia with macrocytosis. Br J Haematol 1997; 97:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/37\">",
"      Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/38\">",
"      Raskind WH, Wijsman E, Pagon RA, et al. X-linked sideroblastic anemia and ataxia: linkage to phosphoglycerate kinase at Xq13. Am J Hum Genet 1991; 48:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/39\">",
"      Cox TC, Kozman HM, Raskind WH, et al. Identification of a highly polymorphic marker within intron 7 of the ALAS2 gene and suggestion of at least two loci for X-linked sideroblastic anemia. Hum Mol Genet 1992; 1:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/40\">",
"      Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/41\">",
"      Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000; 96:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/42\">",
"      Maguire A, Hellier K, Hammans S, May A. X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001; 115:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/43\">",
"      D'Hooghe M, Selleslag D, Mortier G, et al. X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol 2012; 16:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/44\">",
"      Pondarre C, Campagna DR, Antiochos B, et al. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007; 109:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/45\">",
"      Lill R, M&uuml;hlenhoff U. Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases. Annu Rev Biochem 2008; 77:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/46\">",
"      Casas KA, Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia. Am J Med Genet A 2004; 125A:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/47\">",
"      Bykhovskaya Y, Casas K, Mengesha E, et al. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 2004; 74:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/48\">",
"      Zeharia A, Fischel-Ghodsian N, Casas K, et al. Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis: an autosomal recessive syndrome in Persian Jews caused by a mutation in the PUS1 gene. J Child Neurol 2005; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/49\">",
"      Fernandez-Vizarra E, Berardinelli A, Valente L, et al. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA). J Med Genet 2007; 44:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/50\">",
"      Patton JR, Bykhovskaya Y, Mengesha E, et al. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem 2005; 280:19823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/51\">",
"      Sasarman F, Nishimura T, Thiffault I, Shoubridge EA. A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia. Hum Mutat 2012; 33:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/52\">",
"      Manea EM, Leverger G, Bellmann F, et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J Pediatr Hematol Oncol 2009; 31:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/53\">",
"      R&ouml;tig A, Bourgeron T, Chretien D, et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995; 4:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/54\">",
"      Bader-Meunier B, Mi&eacute;lot F, Breton-Gorius J, et al. Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999; 46:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/55\">",
"      Neufeld EJ, Fleming JC, Tartaglini E, Steinkamp MP. Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. Blood Cells Mol Dis 2001; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/56\">",
"      Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999; 22:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/57\">",
"      Fleming JC, Tartaglini E, Steinkamp MP, et al. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 1999; 22:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/58\">",
"      Diaz GA, Banikazemi M, Oishi K, et al. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 1999; 22:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/59\">",
"      Bergmann AK, Sahai I, Falcone JF, et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/60\">",
"      Baron D, Assaraf YG, Cohen N, Aronheim A. Lack of plasma membrane targeting of a G172D mutant thiamine transporter derived from Rogers syndrome family. Mol Med 2002; 8:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/61\">",
"      Subramanian VS, Marchant JS, Parker I, Said HM. Cell biology of the human thiamine transporter-1 (hTHTR1). Intracellular trafficking and membrane targeting mechanisms. J Biol Chem 2003; 278:3976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/62\">",
"      Boros LG, Steinkamp MP, Fleming JC, et al. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 2003; 102:3556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/63\">",
"      Abboud MR, Alexander D, Najjar SS. Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficient alpha-ketoglutarate dehydrogenase activity. J Pediatr 1985; 107:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/64\">",
"      Ricketts CJ, Minton JA, Samuel J, et al. Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families. Acta Paediatr 2006; 95:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/65\">",
"      Kushner JP, Lee GR, Wintrobe MM, Cartwright GE. Idiopathic refractory sideroblastic anemia: clinical and laboratory investigation of 17 patients and review of the literature. Medicine (Baltimore) 1971; 50:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/66\">",
"      May A, Al-Sabah AI, Lawlwss SL. Acquired sideroblastic anemia unresponsive to pyridoxine caused by a somatic mutation in ALA synthase 2 (Abstract). Blood 2005; 106:988a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/67\">",
"      Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988; 25:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/68\">",
"      Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol 2006; 155:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/69\">",
"      Boultwood J, Pellagatti A, Nikpour M, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3:e1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/70\">",
"      Wulfert M, K&uuml;pper AC, Tapprich C, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008; 36:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/71\">",
"      Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/72\">",
"      Gattermann N. Mitochondrial DNA mutations in the hematopoietic system. Leukemia 2004; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/73\">",
"      Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/74\">",
"      Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/75\">",
"      Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/76\">",
"      Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/77\">",
"      Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/78\">",
"      Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/79\">",
"      Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 2013; 98:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/80\">",
"      Eichner ER, Hillman RS. The evolution of anemia in alcoholic patients. Am J Med 1971; 50:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/81\">",
"      Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/82\">",
"      Meagher RC, Sieber F, Spivak JL. Suppression of hematopoietic-progenitor-cell proliferation by ethanol and acetaldehyde. N Engl J Med 1982; 307:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/83\">",
"      Burke JP, Rubin E. The effects of ethanol and acetaldehyde on the products of protein synthesis by liver mitochondria. Lab Invest 1979; 41:393.",
"     </a>",
"    </li>",
"    <li>",
"     Bottomley SS. Sideroblastic anaemia. In: Iron in Biochemistry and Medicine II, Jacobs A, Worwood M (Eds), Academic Press, London 1980. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/85\">",
"      Colucci G, Silzle T, Solenthaler M. Pyrazinamide-induced sideroblastic anemia. Am J Hematol 2012; 87:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/86\">",
"      Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/87\">",
"      Yunis AA, Adamson JW. Differential in vitro sensitivity of marrow erythroid and granulocytic colony forming cells to chloramphenicol. Am J Hematol 1977; 2:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/88\">",
"      Saini N, Jacobson JO, Jha S, et al. The perils of not digging deep enough--uncovering a rare cause of acquired anemia. Am J Hematol 2012; 87:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/89\">",
"      Peled T, Glukhman E, Hasson N, et al. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol 2005; 33:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/90\">",
"      Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/91\">",
"      Madsen E, Gitlin JD. Copper deficiency. Curr Opin Gastroenterol 2007; 23:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/92\">",
"      Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007; 30:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/37/36441/abstract/93\">",
"      O'Brien H, Amess JA, Mollin DL. Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol 1982; 51:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7124 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-2F8CF27215-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36441=[""].join("\n");
var outline_f35_37_36441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11025473\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONGENITAL SIDEROBLASTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      X-linked sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - 5-Aminolevulinate synthase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Functional effects of mutant ALAS2 enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Molecular basis for pyridoxine responsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mitochondrial transporter SLC25A38 defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glutaredoxin 5 (GLRX5) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Congenital sideroblastic anemia without identified molecular defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sideroblastic anemia as a component of genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - X-linked sideroblastic anemia with ataxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Myopathy, lactic acidosis, and sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1551515\">",
"      - Pearson marrow-pancreas syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Thiamine-responsive megaloblastic anemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACQUIRED CLONAL SIDEROBLASTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACQUIRED METABOLIC SIDEROBLASTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Isoniazid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chloramphenicol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1551200\">",
"      - Linezolid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Copper deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Zinc toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neurologic and hematologic syndrome associated with copper deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DISORDERS OF ERYTHROID HEME SYNTHESIS WITHOUT RING SIDEROBLASTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11025473\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7124|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/56/24455\" title=\"figure 1\">",
"      Mitochondrial pathways congenital sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/30/6639\" title=\"figure 2\">",
"      Mutations in ALA synthase gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/39/6773\" title=\"figure 3\">",
"      Pathway of hemoglobin synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/3/9276\" title=\"table 1\">",
"      Causes of sideroblastic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5656?source=related_link\">",
"      ALA dehydratase porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35750?source=related_link\">",
"      Pathophysiology of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_37_36442="ACR relative radiation 1";
var content_f35_37_36442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70717%7ERHEUM%2F50652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70717%7ERHEUM%2F50652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    ACR relative radiation information (Part 1 of 2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 740px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Royal College of Radiologists. Making the best use of a department of clinical radiology: guidelines for doctors. 5th ed. London: The Royal College of Radiologists; 2003.",
"       </li>",
"       <li>",
"        Martin CJ. Effective dose: how should it be applied to medical exposures? Br J Radiol 2007; 80(956):639-647.",
"       </li>",
"       <li>",
"        International Commission on Radiological Protection, 1990 Recommendations of the International Commission on Radiological Protection, ICRP Publication 60. Ann ICRP 1991; 21:1-3.",
"       </li>",
"       <li>",
"        Bor D, Sancak T, Olgar T, et al. Comparison of effective doses obtained from dose-area product and air kerma measurements in interventional radiology. Br J Radiol 2004; 77(916):315-322.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Exposure of the US population from diagnostic medical radiation, NCRP Report No. 100. Bethesda, MD; 1989.",
"       </li>",
"       <li>",
"        Conference of Radiation Control Program Directors. Nationwide Evaluation of X-Ray Trends (NEXT) - Tabulation and Graphical Summary of 2000 Survey of Computed Tomography: file://www.fda.gov/cdrh/ct/2000survey.html; 2007: In publication: CRCPD publication no. E-07-02.",
"       </li>",
"       <li>",
"        United States Pharmacopeia Drug Information: Drug Information for the Health Care Professional. 27th ed. Greenwood Village, CO: Thomson Micromedex; 2007.",
"       </li>",
"       <li>",
"        ICRP Publication 80: Radiation Dose to Patients from Radiopharmaceuticals. Rev ed: Elsevier; September 1, 1999.",
"       </li>",
"       <li>",
"        Mettler FA, Jr., Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248(1):254-263.",
"       </li>",
"       <li>",
"        Wall BF, Hart D. Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. Br J Radiol 1997; 70(833):437-439.",
"       </li>",
"       <li>",
"        Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Ionizing radiation exposure of the population of the United States., NCRP Report No. 93. Bethesda, MD; 1987.",
"       </li>",
"       <li>",
"        Amis ES, Jr., Butler PF, Applegate KE, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 2007; 4(5):272-284.",
"       </li>",
"       <li>",
"        National Cancer Institute. Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers. file://www.cancer.gov/cancertopics/causes/radiation-risks-pediatric-CT. Accessed August 2009.",
"       </li>",
"       <li>",
"        ACR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. In: Practice Guidelines and Technical Standards. Reston, Va: American College of Radiology; 2008:23-37.",
"       </li>",
"      </ol>",
"      American College of Radiology Appropriateness Criteria.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    ACR relative radiation information (Part 2 of 2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 669px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Royal College of Radiologists. Making the best use of a department of clinical radiology: guidelines for doctors. 5th ed. London: The Royal College of Radiologists; 2003.",
"       </li>",
"       <li>",
"        Martin CJ. Effective dose: how should it be applied to medical exposures? Br J Radiol 2007; 80(956):639-647.",
"       </li>",
"       <li>",
"        International Commission on Radiological Protection, 1990 Recommendations of the International Commission on Radiological Protection, ICRP Publication 60. Ann ICRP 1991; 21:1-3.",
"       </li>",
"       <li>",
"        Bor D, Sancak T, Olgar T, et al. Comparison of effective doses obtained from dose-area product and air kerma measurements in interventional radiology. Br J Radiol 2004; 77(916):315-322.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Exposure of the US population from diagnostic medical radiation, NCRP Report No. 100. Bethesda, MD; 1989.",
"       </li>",
"       <li>",
"        Conference of Radiation Control Program Directors. Nationwide Evaluation of X-Ray Trends (NEXT) - Tabulation and Graphical Summary of 2000 Survey of Computed Tomography: file://www.fda.gov/cdrh/ct/2000survey.html; 2007: In publication: CRCPD publication no. E-07-02.",
"       </li>",
"       <li>",
"        United States Pharmacopeia Drug Information: Drug Information for the Health Care Professional. 27th ed. Greenwood Village, CO: Thomson Micromedex; 2007.",
"       </li>",
"       <li>",
"        ICRP Publication 80: Radiation Dose to Patients from Radiopharmaceuticals. Rev ed: Elsevier; September 1, 1999.",
"       </li>",
"       <li>",
"        Mettler FA, Jr., Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248(1):254-263.",
"       </li>",
"       <li>",
"        Wall BF, Hart D. Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. Br J Radiol 1997; 70(833):437-439.",
"       </li>",
"       <li>",
"        Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Ionizing radiation exposure of the population of the United States., NCRP Report No. 93. Bethesda, MD; 1987.",
"       </li>",
"       <li>",
"        Amis ES, Jr., Butler PF, Applegate KE, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 2007; 4(5):272-284.",
"       </li>",
"       <li>",
"        National Cancer Institute. Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers. file://www.cancer.gov/cancertopics/causes/radiation-risks-pediatric-CT. Accessed August 2009.",
"       </li>",
"       <li>",
"        ACR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. In: Practice Guidelines and Technical Standards. Reston, Va: American College of Radiology; 2008:23-37.",
"       </li>",
"      </ol>",
"      American College of Radiology Appropriateness Criteria.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36442=[""].join("\n");
var outline_f35_37_36442=null;
var title_f35_37_36443="Modalities photoepilation";
var content_f35_37_36443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modalities for photoepilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       System",
"      </td>",
"      <td class=\"subtitle1\">",
"       Skin types*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Advantages",
"      </td>",
"      <td class=\"subtitle1\">",
"       Disadvantages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1064 nm Nd-YAG",
"      </td>",
"      <td>",
"       I-VI",
"      </td>",
"      <td>",
"       Good for darker skin types",
"      </td>",
"      <td>",
"       <p>",
"        - Pain",
"       </p>",
"       <p>",
"        - Possible folliculitis",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       755 nm alexandrite",
"      </td>",
"      <td>",
"       I-III",
"      </td>",
"      <td>",
"       Good for lighter hair",
"      </td>",
"      <td>",
"       <p>",
"        - Pain",
"       </p>",
"       <p>",
"        - Possible folliculitis",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       810 nm diode",
"      </td>",
"      <td>",
"       I-V",
"      </td>",
"      <td>",
"       Good for darker skin types",
"      </td>",
"      <td>",
"       <p>",
"        - Pain",
"       </p>",
"       <p>",
"        - Possible folliculitis",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IPL&bull;",
"      </td>",
"      <td>",
"       I-IV",
"      </td>",
"      <td>",
"       Less expensive system to purchase",
"      </td>",
"      <td>",
"       - May not be as effective as laser systems",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Fitzpatrick skin types:",
"     <br>",
"      - I - always burns, never tans;",
"      <br>",
"       - II - always burns, sometimes tans;",
"       <br>",
"        - III - sometimes burns, always tans;",
"        <br>",
"         - IV - rarely burns, always tans;",
"         <br>",
"          - V - moderately pigmented;",
"          <br>",
"           - VI - darkly pigmented",
"           <br>",
"            &bull; Intense pulsed light.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36443=[""].join("\n");
var outline_f35_37_36443=null;
var title_f35_37_36444="Rx for hepatic fibrosis";
var content_f35_37_36444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic strategies for hepatic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Strategies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Remove injurious stimuli",
"       </td>",
"       <td>",
"        Abstinence from alcohol for alcoholic liver diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiviral therapy for viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihelminthic therapy for schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper chelation for Wilson's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phlebotomy for hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinue hepatotoxins (eg, methotrexate) in drug-induced liver injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Suppress hepatic inflammation",
"       </td>",
"       <td>",
"        Corticosteroids in autoimmune and alcoholic liver diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutralizing inflammatory cytokines using specific receptor antagonists: IL-1 receptor antagonists, soluble TNF-alpha receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ursodeoxycholic acid (UDCA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Others: prostaglandin E, colchicine and colchiceine, milotilate, translast, IL-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"14\">",
"        Downregulate stellate cell activation",
"       </td>",
"       <td>",
"        Gamma Interferon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antioxidants: alpha-tocopherol, resveratrol, quercetin, N-acetylcysteine, silymarin, OC-15161",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cytokine-directed therapy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        TGF-beta antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Endothelin receptor antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatic growth factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disrupt ECM-HSC interactions: Arg-Gly-Asp (RGD) analogue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Collagen synthesis inhibitors:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        TGF-beta antagonists, relaxin, halofuginone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Others:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dilinoleylphosphotidylcholine (DLPC), HMG CoA reductase,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pentoxyphylline, HOE077, Safironil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retinoids?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herbal medicine: Sho-saiko-to (Xiao-Chaihu-Tang), Salvia miltiorrhiza (Dan-Shen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Promote matrix degradation",
"       </td>",
"       <td>",
"        Target degradation of interstitial-type matrix, rather than basement membrane-type matrix",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGF-beta antagonists, relaxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Promote specific apoptosis of hepatic stellate cells",
"       </td>",
"       <td>",
"        Not yet available",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36444=[""].join("\n");
var outline_f35_37_36444=null;
var title_f35_37_36445="LDL phenotypes and HDL";
var content_f35_37_36445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    LDL phenotypes and HDL-cholesterol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent cumulative frequency of HDL-cholesterol levels according to LDL phenotypes A and B. Phenotype B (solid line) is associated with lower HDL levels and a higher risk of coronary heart disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Austin MA, King MC, Vranizan KM, Krauss RM. Circulation 1990; 82:495.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36445=[""].join("\n");
var outline_f35_37_36445=null;
var title_f35_37_36446="Resolution VUR";
var content_f35_37_36446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resolution nomogram table for girls with unilateral vesicoureteral reflux (VUR) and boys with either unilateral or bilateral VUR",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ureteral anatomy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to resolution (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 4-5 percent (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         Prenatal hydronephrosis/Sibling VUR",
"        </strong>",
"       </td>",
"       <td rowspan=\"10\">",
"        Single",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        55 (48, 61)",
"       </td>",
"       <td>",
"        46 (41, 50)",
"       </td>",
"       <td>",
"        35 (32, 39)",
"       </td>",
"       <td>",
"        24 (20, 27)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        79 (72, 85)",
"       </td>",
"       <td>",
"        70 (65, 74)",
"       </td>",
"       <td>",
"        58 (54, 62)",
"       </td>",
"       <td>",
"        41 (36, 46)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        88 (82, 92)",
"       </td>",
"       <td>",
"        81 (77, 85)",
"       </td>",
"       <td>",
"        69 (65, 73)",
"       </td>",
"       <td>",
"        52 (45, 57)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        93 (88, 96)",
"       </td>",
"       <td>",
"        87 (83, 90)",
"       </td>",
"       <td>",
"        77 (73, 81)",
"       </td>",
"       <td>",
"        60 (53, 66)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        96 (92, 98)",
"       </td>",
"       <td>",
"        91 (88, 94)",
"       </td>",
"       <td>",
"        83 (78, 86)",
"       </td>",
"       <td>",
"        66 (59, 72)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1&nbsp;year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        45 (38, 51)",
"       </td>",
"       <td>",
"        37 (33, 41)",
"       </td>",
"       <td>",
"        28 (25, 31)",
"       </td>",
"       <td>",
"        18 (15, 22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        70 (62, 76)",
"       </td>",
"       <td>",
"        60 (55, 65)",
"       </td>",
"       <td>",
"        48 (43, 53)",
"       </td>",
"       <td>",
"        33 (28, 38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        81 (73, 86)",
"       </td>",
"       <td>",
"        72 (66, 77)",
"       </td>",
"       <td>",
"        59 (54, 64)",
"       </td>",
"       <td>",
"        43 (36, 48)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        87 (80, 91)",
"       </td>",
"       <td>",
"        79 (74, 84)",
"       </td>",
"       <td>",
"        68 (62, 72)",
"       </td>",
"       <td>",
"        50 (42, 56)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        91 (85, 95)",
"       </td>",
"       <td>",
"        85 (79, 89)",
"       </td>",
"       <td>",
"        74 (68, 78)",
"       </td>",
"       <td>",
"        56 (48, 63)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Duplication",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1&nbsp;year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        40 (32, 48)",
"       </td>",
"       <td>",
"        33 (27, 38)",
"       </td>",
"       <td>",
"        25 (20, 29)",
"       </td>",
"       <td>",
"        16 (12, 19)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        64 (53, 72)",
"       </td>",
"       <td>",
"        55 (46, 62)",
"       </td>",
"       <td>",
"        43 (36, 49)",
"       </td>",
"       <td>",
"        29 (23, 35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        75 (64, 83)",
"       </td>",
"       <td>",
"        66 (57, 73)",
"       </td>",
"       <td>",
"        54 (46, 61)",
"       </td>",
"       <td>",
"        38 (30, 44)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        83 (72, 89)",
"       </td>",
"       <td>",
"        74 (65, 81)",
"       </td>",
"       <td>",
"        62 (53, 69)",
"       </td>",
"       <td>",
"        45 (36, 52)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        87 (78, 93)",
"       </td>",
"       <td>",
"        80 (71, 86)",
"       </td>",
"       <td>",
"        68 (59, 75)",
"       </td>",
"       <td>",
"        50 (41, 58)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        32 (25, 39)",
"       </td>",
"       <td>",
"        26 (21, 31)",
"       </td>",
"       <td>",
"        19 (15, 23)",
"       </td>",
"       <td>",
"        12 (9, 15)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        54 (43, 63)",
"       </td>",
"       <td>",
"        45 (37, 52)",
"       </td>",
"       <td>",
"        35 (28, 41)",
"       </td>",
"       <td>",
"        23 (18, 28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        65 (54, 74)",
"       </td>",
"       <td>",
"        56 (47, 64)",
"       </td>",
"       <td>",
"        44 (36, 51)",
"       </td>",
"       <td>",
"        30 (23, 36)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        73 (62, 82)",
"       </td>",
"       <td>",
"        64 (54, 72)",
"       </td>",
"       <td>",
"        52 (43, 59)",
"       </td>",
"       <td>",
"        36 (28, 43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        79 (68, 87)",
"       </td>",
"       <td>",
"        70 (60, 78)",
"       </td>",
"       <td>",
"        58 (49, 66)",
"       </td>",
"       <td>",
"        41 (32, 49)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         History of urinary tract infection",
"        </strong>",
"       </td>",
"       <td rowspan=\"10\">",
"        Single",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1 year&nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        47 (41, 53)",
"       </td>",
"       <td>",
"        39 (35, 42)",
"       </td>",
"       <td>",
"        30 (27, 33)",
"       </td>",
"       <td>",
"        19 (16, 23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        72 (65, 78)",
"       </td>",
"       <td>",
"        62 (58, 66)",
"       </td>",
"       <td>",
"        50 (46, 54)",
"       </td>",
"       <td>",
"        35 (30, 40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        82 (76, 87)",
"       </td>",
"       <td>",
"        74 (69, 78)",
"       </td>",
"       <td>",
"        62 (57, 66)",
"       </td>",
"       <td>",
"        44 (38, 50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        88 (83, 92)",
"       </td>",
"       <td>",
"        81 (77, 85)",
"       </td>",
"       <td>",
"        70 (65, 74)",
"       </td>",
"       <td>",
"        52 (45, 58)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        92 (88, 95)",
"       </td>",
"       <td>",
"        86 (82, 89)",
"       </td>",
"       <td>",
"        76 (71, 80)",
"       </td>",
"       <td>",
"        58 (50, 65)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1&nbsp;year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        38 (33, 43)",
"       </td>",
"       <td>",
"        31 (28, 34)",
"       </td>",
"       <td>",
"        24 (21, 26)",
"       </td>",
"       <td>",
"        15 (13, 18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        62 (55, 68)",
"       </td>",
"       <td>",
"        52 (49, 56)",
"       </td>",
"       <td>",
"        41 (38, 44)",
"       </td>",
"       <td>",
"        28 (23, 32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        73 (66, 79)",
"       </td>",
"       <td>",
"        64 (60, 68)",
"       </td>",
"       <td>",
"        52 (48, 55)",
"       </td>",
"       <td>",
"        36 (30, 41)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        81 (74, 86)",
"       </td>",
"       <td>",
"        72 (68, 76)",
"       </td>",
"       <td>",
"        60 (55, 63)",
"       </td>",
"       <td>",
"        43 (36, 48)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        86 (80, 90)",
"       </td>",
"       <td>",
"        78 (74, 81)",
"       </td>",
"       <td>",
"        66 (61, 70)",
"       </td>",
"       <td>",
"        48 (41, 55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Duplication",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1&nbsp;year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        34 (27, 41)",
"       </td>",
"       <td>",
"        27 (22, 32)",
"       </td>",
"       <td>",
"        21 (17, 24)",
"       </td>",
"       <td>",
"        13 (10, 16)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        56 (46, 64)",
"       </td>",
"       <td>",
"        47 (40, 54)",
"       </td>",
"       <td>",
"        37 (30, 42)",
"       </td>",
"       <td>",
"        24 (19, 29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        68 (57, 76)",
"       </td>",
"       <td>",
"        58 (50, 65)",
"       </td>",
"       <td>",
"        46 (39, 53)",
"       </td>",
"       <td>",
"        32 (25, 38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        76 (65, 83)",
"       </td>",
"       <td>",
"        66 (57, 73)",
"       </td>",
"       <td>",
"        54 (46, 61)",
"       </td>",
"       <td>",
"        38 (30, 45)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        81 (71, 88)",
"       </td>",
"       <td>",
"        72 (64, 79)",
"       </td>",
"       <td>",
"        60 (51, 67)",
"       </td>",
"       <td>",
"        43 (34, 51)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        27 (21, 33)",
"       </td>",
"       <td>",
"        22 (18, 25)",
"       </td>",
"       <td>",
"        16 (13, 19)",
"       </td>",
"       <td>",
"        10 (8, 13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        47 (38, 54)",
"       </td>",
"       <td>",
"        38 (32, 44)",
"       </td>",
"       <td>",
"        29 (24, 34)",
"       </td>",
"       <td>",
"        19 (15, 23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        58 (47, 66)",
"       </td>",
"       <td>",
"        48 (41, 55)",
"       </td>",
"       <td>",
"        38 (31, 44)",
"       </td>",
"       <td>",
"        25 (20, 30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        66 (55, 74)",
"       </td>",
"       <td>",
"        56 (48, 63)",
"       </td>",
"       <td>",
"        45 (37, 51)",
"       </td>",
"       <td>",
"        30 (24, 37)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        72 (61, 80)",
"       </td>",
"       <td>",
"        62 (54, 70)",
"       </td>",
"       <td>",
"        50 (42, 57)",
"       </td>",
"       <td>",
"        35 (27, 42)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean predicted rates of cumulative annual spontaneous resolution of primary VUR based upon the age of the patient and the VUR grade expressed as percentage of cases.",
"    <div class=\"footnotes\">",
"     <p>",
"      %: percent; CI: confidence interval.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Estrada CR Jr, Passerotti CC, Graham DA, et al. Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2462 children. J Urol 2009; 182:1535. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36446=[""].join("\n");
var outline_f35_37_36446=null;
var title_f35_37_36447="Cardiotography showing calculation of Montevideo units";
var content_f35_37_36447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Cardiotography showing calculation of Montevideo units",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Montevideo units are calculated by subtracting the baseline uterine pressure from the peak contraction pressure of each contraction (red arrows) in a 10-minute window and adding the pressures generated by each contraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_37_36447=[""].join("\n");
var outline_f35_37_36447=null;
